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The eukaryotic genome is stored in the nucleus as chromatin, a dynamic 
structure of DNA and histone proteins. Chromatin contains a vast array of features that 
directs how, when, and where genomic DNA is made accessible by regulatory 
machinery. These features facilitate homeostatic cell programs, whereas their 
misregulation is a hallmark of cancer where endogenous regulatory programs are co-
opted to promote aberrant signaling.  
In Chapter 1, I introduce four classes of proteins and protein complexes, among 
others, that regulate chromatin. I describe seminal discoveries that indicate these 
classes operate within elaborate networks that direct genomic output. In Chapter 2, I 
outline the roles that the class of ATP-dependent chromatin remodeling enzymes, 
nicknamed movers, serves in chromatin regulation. Chapters 3 and 4 describe our 
ongoing efforts to elucidate the mechanism by which a mover, named INO80-C, targets 
chromatin and identifies suitable genomic loci for regulation. We leveraged genomics 
approaches, biochemistry, and molecular biology to characterize the genomic targeting 
and molecular function of INO80-C in human cells. Chapter 3 details our observation 
that INO80-C is not a uniform biochemical complex at all sites across the genome, in
 iv 
contrast to expectations based on the literature. Chapter 4 demonstrates our efforts to 
delineate the function of INO80-C at its genomic targets, including our exploration of an 
antagonistic relationship with a histone methyltransferase named Polycomb Repressive 
Complex 2. Collectively, these data indicate that INO80-C engages in meaningful 
crosstalk with other chromatin regulators and features at its genomic targets. In Chapter 
5, I draw conclusions from my research and place the findings into a broader context. 
Additionally, I describe the implications that my work may have on translational topics, 
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CHAPTER 1: REGULATION OF CHROMATIN BY READERS, WRITERS, ERASERS, 
AND MOVERS 
 
Introduction to Chromatin 
Eukaryotes evolved to store DNA in the form of chromatin, a complex structure 
comprised of histone proteins (H2A, H2B, H3, H4) and double-helixed nucleic acids. 
Eight histone proteins form the nucleosome, around which segments of DNA 
approximately 147 base pairs in length are wrapped. Storing DNA in this manner allows 
for efficient packaging of the coding and non-coding information in DNA to fit within the 
nucleus. To reprise a famous example of the tremendous storage capacity of chromatin, 
a single human genome contains 2 meters of DNA compacted into a nucleus which is 
only 10 micrometers in diameter (Wu 2012). Over decades, many studies have shown 
that chromatin serves a greater function than simply acting as a DNA storage molecule. 
Indeed, an array of chromatin-based signals provides valuable information to a cell 
regarding the utility of genomic regions.  
The nucleosome is the core unit of chromatin. Nucleosomes are highly dynamic 
structures that are subject to multivalent regulation. They can be variable in histone 
protein composition (Maze et al. 2014; Talbert and Henikoff 2017), undergo a wide 
array of post-translational modifications (Strahl and Allis 2000; Gardner et al. 2011; Tan 
et al. 2011; Allis and Jenuwein 2016), and are subject to changes in their localization at 
genomic sites (Wu 2012; Lai and Pugh 2017). These variations in nucleosome biology
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instruct cells how to utilize epigenomic loci and the underlying DNA sequences. 
As a result, regulation of chromatin delivers precise instructions to cells leading to 
secondary processes that are physiologically critical (Fazzio and Panning 2010; Lee 
and Young 2013; Buschbeck and Hake 2017; Atlasi and Stunnenberg 2017; Marazzi et 
al. 2017; Theunissen and Jaenisch 2017). In essence, beyond serving as a DNA 
storage molecule, chromatin serves as a template that enables cells to leverage 
multivalent signals surrounding genomic sites as instructions to cellular machinery for 
biological programs. The variety of regulators that cells evolved to control these 
programs are the focus of this chapter. 
 
Four Types of Chromatin Regulators 
Generally, there are three categories of proteins and enzymes that reversibly 
modify chromatin. They either deposit, remove, or recognize post-translational 
modifications (PTMs) onto the unstructured tails of histone proteins, earning nicknames 
as writers, erasers, and readers, respectively (Gardner et al. 2011). Together, these 
proteins are considered the primary determinants of the “histone code hypothesis” 
(Strahl and Allis 2000). According to this hypothesis, individual histone PTMs or sets of 
histone PTMs provide an interpretable system of chromatin signals with specific 
outputs. Over time, debate has emerged regarding the existence of a strict code for 
histone PTM readout generated by writers, erasers, and readers, and other elements of 
chromatin. Proponents suggest histone signatures specify locus regulation according to 
a highly specific code contained in PTMs. Opponents argue that arrays of histone PTMs 
may be largely interpretable by cells, but also serve separate functions depending on 
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cellular context (Lee et al. 2010; Henikoff and Shilatifard 2011), thus rendering the 
“code” flexible, not strict. Debate aside, abundant evidence makes it clear that writers, 
erasers, and readers constitute an essential component of chromatin signaling (Gardner 
et al. 2011).  
Readers, writers, and erasers have been proven to drive changes in chromatin 
accessibility, such as generating inactive heterochromatin or active euchromatin, or 
maintaining chromatin states throughout cellular changes (Gardner et al. 2011; Wu 
2012; Allis and Jenuwein 2016). Although widely appreciated for their contributions to 
chromatin outcomes, a separate class of chromatin regulator has not been frequently 
discussed in relation to readers, writers, and erasers. ATP-dependent chromatin 
remodelers, nicknamed movers, contribute to chromatin states by regulating 
nucleosome units, likely in conjunction with readers, writers, and erasers. Herein, we 
focus on the roles of these four regulators and the integrative function each class plays 
in directing chromatin regulation and in turn, gene expression programs (Fig. 1.1).  
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Figure 1.1. Representative Functions of Each Class of Chromatin Regulator.  
A. Readers recognize PTMs, such as H3K27ac by bromodomain-containing BRD4. B. 
Writers deposit histone PTMs, for example the SET-domain containing histone 
methyltransferase EZH2 of the Polycomb Repressive Complex 2. C. Erasers remove 
histone PTMs, including the Jumonji-C domain containing lysine demethylase UTX. D. 
Movers target entire nucleosome structures, e.g. SWI/SNF which contains nucleosome 
targeting components and a catalytic ATPase that breaks histone-DNA contacts then 





Readers are proteins that contain peptide domains to recognize modifications to 
the unstructured N terminal tails of histones. One function of readers is to propagate 
signaling cascades downstream from the modification itself, by recruiting secondary 
proteins or sets of proteins to facilitate a biological output. One classic example of 
readers are BET (bromodomain and external terminal domain) family proteins. BET 
family proteins (BRD2, BRD3, BRD4, BRDT) contain bromodomains, which have high 
affinity for acetylated lysines (Stathis and Bertoni 2017). There are an estimated 42 
proteins that contain bromodomains, and in some cases multiple bromodomains are 
present within a single protein (Filippakopoulos et al. 2010). Evidence suggests that the 
multitude of proteins containing bromodomains implicates the recognition of lysine 
acetylation as an important signal for nuclear biology (Sanchez and Zhou 2009). 
Moreover, bromodomain-containing proteins often contain additional functional 
domains, such as DNA-binding PHD fingers, or they physically interact with other 
proteins that confer secondary chromatin-based functions, such as the PBRM1 protein 
which contains six bromodomains and is a stable subunit of the the SWI/SNF chromatin 
remodeling complex (Sanchez and Zhou 2009). Notably, BET family proteins are 
locationally over-represented at promoters and enhancers of active genes making the 
investigation of their role in gene regulation a topic of widespread interest. 
Because acetylated lysines are a hallmark of active chromatin regions (Gardner 
et al. 2011), BET family proteins have gained notoriety for their involvement in 
propagating oncogenic signals in cancer. For example, in NUT midline carcinoma, a 
fusion event between the BET family protein BRD4 (or less commonly BRD3) and the 
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NUT protein is a hallmark molecular characteristic (French 2014). Genomic 
characterization of these tumors has revealed that the BRD-NUT fusion targets large 
topological domains of acetylated lysines on chromatin, including regions that drive 
constitutive activation the MYC oncogene (Alekseyenko et al. 2015). The prevailing 
model suggests that BRD-NUT fusions sequester histone acetyltransferase machinery, 
leading to the establishment of large acetylated domains from existing enhancer loci 
(French 2014; Alekseyenko et al. 2015).  
In other tumors, BRD4 has been identified as a tumor cell dependency, where 
BRD4 localizes to regulatory regions that promote cell growth (Lovén et al. 2013; 
Chapuy et al. 2013; Lin et al. 2016; Zawistowski et al. 2017). Attempts to ablate its 
function have yielded cell death and tumor regression in several contexts (Zuber et al. 
2011; Delmore et al. 2011; Shi et al. 2015). As a result, several BET inhibitors have 
been released and entered into clinical trials (Stathis and Bertoni 2017). The goal of the 
inhibitors is to prevent BET family proteins from recognizing acetylated lysine residues 
and to abrogate the signaling cascade that occurs at the level of acetylated chromatin in 
cancer. The approach has generated some signs of promise as a therapy, particularly in 
NUT midline carcinoma and several hematologic malignancies where aberrant histone 
acetylation is a common characteristic (Stathis and Bertoni 2017).  
Additionally, the ability of BET family proteins to facilitate oncogenic programs 
simply through recognizing acetylated lysines, and their susceptibility to therapeutic 
intervention, indicates that readers are a critical component of chromatin regulation that 
promote chromatin-related signaling with biological effects that extend beyond the 
nucleus and transcription. Analogous readers exist for other histone PTMs including 
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methylation, sumoylation, ubiquitylation, crotonylation, and others, some of which have 
been discovered and others that are under active investigation (Musselman et al. 2012). 
The array of modifications, and the array of signaling pathways likely derived from them, 
emphasizes the constellation of readouts and downstream functions of chromatin 
regulation. In summary, reader proteins such as BET family proteins represent critical 




Writers are perhaps the most well-studied histone modifying proteins. Their 
discovery represents one of the most prominent moments of chromatin biology. Writers 
deposit modifications to histones, creating new landscapes of histone modifications 
genome-wide or at specific sites de novo. In 1996, after years of correlative evidence 
suggesting a relationship between histone acetylation and active chromatin regions 
(Allfrey et al. 1964; Csordas 1990; Turner 1993; Wolffe 1994; Loidl 1994) Brownell et al. 
first reported that a histone acetyltransferase, GCN5, is recruited to the nucleus to 
acetylate targets on chromatin (Brownell et al. 1996). This marked a link between 
chromatin modifying enzymes and transcriptional output for the first time. Some 
evidence for a direct relationship between histone acetylation and transcriptional 
activation had been reported prior to this seminal discovery (Hebbes et al. 1988, 1994), 
however it was not understood how chromatin came to be modified and it was unclear 
what the direct functional output was.  
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In a report published shortly after the initial discovery (Brownell et al. 1996), it 
was determined that histone acetylation on chromatin was specific to sets of residues 
within histone tails (Kuo et al. 1996). These data suggested that modification of 
chromatin was likely to be a tightly regulated and highly specific phenomenon. These 
two foundational discoveries launched decades of work to determine where and why 
modifications to chromatin occur. In the years since, dozens of other writer proteins 
have been discovered to play important roles in diverse biological processes (Gardner 
et al. 2011).  
Histone acetyltransferases (HATs) are particularly potent writer enzymes. In 
mammals, two proteins, among many others, are particularly relevant to our discussion 
of histone tail acetylation: CBP and P300. These two proteins possess the ability to 
acetylate both histone and non-histone nuclear substrates (Ogryzko et al. 1996; Blobel 
2000), but their primary role is believed to be acetylation of lysine 27 on histone 3 
(H3K27ac) (Creyghton et al. 2010). Additionally, both CBP and P300 are ubiquitously 
expressed throughout development, (Partanen et al. 1999) and embryonic lethal when 
absent (Kasper et al. 2006). Perturbation of their activity can lead to tumorigenic 
responses suggesting their function is critical to homeostasis (Kasper et al. 2006; 
Roelfsema and Peters 2007; Zhang et al. 2017b). In fact, mice bearing double 
heterozygotic loss of CBP and P300 are not viable (Kalkhoven 2004). These results 
underscore the biological importance of depositing acetylation on histone residues, and 
illustrate the severe consequences that result when chromatin signals are incorrect or 
absent during early stages of animal development.  
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Acetyltransferase-dependent regulatory programs are likely to be particularly 
important at promoters and enhancers (Gardner et al. 2011). P300 binding has been 
used as a reliable surrogate for identifying enhancers (Xi et al. 2007; Visel et al. 2009; 
Heintzman et al. 2009), and H3K27ac can be used to predict transcriptional activity of a 
locus (Karlić et al. 2010; Ernst and Kellis 2012). H3K27ac has been used to distinguish 
active from inactive enhancers (Creyghton et al. 2010). Additionally, H3K27ac is one of 
the few modifications that reliably distinguishes active genomic regions, along with 
H3K4me3 (promoters) (Xi et al. 2007) and H3K4me1 (enhancers) (Heintzman et al. 
2007).  
In addition to their acetyltransferase activity, both CBP and P300 contain 
bromodomains and PHD-finger domains suggesting that they not only initiate histone 
acetylation but also recognize the modification, perhaps for positive regulation of 
acetylated sites (Manning et al. 2001; Deng et al. 2003). The multifunctional 
components of CBP and P300, like other instances throughout chromatin biology, 
represent the elaborate nature of genomic regulation. It seems that specificity, as well 
as potency, of chromatin regulators is critical to biological programs and nature has 
evolved tools to enhance the accuracy of chromatin-regulatory control.  
Inhibition of CBP and P300 has been a topic of interest in cancer research, 
including approaches to abrogate either catalytic activity of the enzymes (Lasko et al. 
2017) or bromodomain-mediated recognition of targets (Conery et al. 2016). Because 
the functions of CBP and P300 are thought to be dependent both on their catalytic 
acetyltransferase activity and their recognition of specific histone targets, both 
approaches hold promise to provide viable therapeutic approaches and insight into their 
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biology. Again, the multivalent activities of CBP and P300 are evidence of the 
complexity of epigenomic regulation and the precision with which the chromatin-based 
machinery functions.  
Notably, the activating role of acetyltransferases is antagonized by writers of 
repressive histone modifications. For example, SET-domain containing lysine 
methyltransferases deposit methyl groups to histone tails, which establishes or 
maintains repressive chromatin on H3K27 (Allis and Jenuwein 2016; Comet et al. 
2016). Importantly, methylation to H3K27 opposes H3K27ac (Tie et al. 2009; Pasini et 
al. 2010; Creyghton et al. 2010). One notable family of SET-domain containing lysine 
methyltransferases are enhancer of zeste proteins EZH1 and EZH2 (Shen et al. 2008; 
Allis and Jenuwein 2016; Comet et al. 2016). These proteins uniquely facilitate H3K27 
methylation. They also form stable, multimeric complexes with additional proteins that 
enable their function (Czermin et al. 2002; Müller et al. 2002; Cao et al. 2002; 
Kuzmichev et al. 2002; Shen et al. 2008; Comet et al. 2016).  
EZH1 and EZH2 methylation activity requires the formation of a complex 
containing suppressor of zeste 12 (SUZ12) and embryonic ectoderm development 
(EED). These proteins facilitate the catalytic activity of EZH1 and EZH2 and enable 
substrate recognition (Nekrasov et al. 2005; Tie et al. 2007; Whitcomb et al. 2007). The 
complexes are termed Polycomb Repressive Complex 2 (PRC2). Additional proteins 
are known to associate with PRC2, such as JARID2 and AEBP2, among others, 
however the core PRC2 complex contains either EZH1 or EZH2, SUZ12, and EED.  
As with HATs, components of histone methyltransferases (HMTs) like PRC2 
subunits EZH1/2, SUZ12, and EED are required for development in mice (Faust et al. 
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1995; O’Carroll et al. 2001; Pasini et al. 2004), underscoring the importance of their 
biological role. Evidence indicates that PRC2 facilitates gene expression programs that 
are required for cell viability, division, or differentiation (Comet et al. 2016). Additionally, 
H3K27 can be monomethylated (H3K27me1), dimethylated (H3K27me2), and 
trimethylated (H3K27me3) by PRC2 with differing genomic distributions and functional 
roles (Scelfo et al. 2015). It is thought that H3K27me3 is a stable modification that leads 
to constitutive repression of underlying genomic targets (Hansen et al. 2008) while 
H3K27me2 marks targets of intermediate-repression and H3K27me1 characterizes 
intergenic regions of actively transcribed genes, an independent H3K27 modification 
signature and readout compared to the repressive H3K27me2 and H3K27me3 (Scelfo 
et al. 2015). Indeed, consistent with H3K27me3 representing a stable modification, 
EZH1/2 exhibit a greater affinity for H3K27me1 than H3K27me2, suggesting that 
achieving H3K27me2 is easier than H3K27me3 (Scelfo et al. 2015). As a result, once a 
locus achieves H3K27me3 it is likely to maintain that status.  
H3K27me3 is the subject of investigative efforts for its role in developmental and 
pathological contexts. In development, PRC2 and H3K27me3 establish and maintain 
cell identity, in part by silencing the transcription of lineage-specifying HOX genes to 
drive differentiation programs (Mallo and Alonso 2013). Other development roles for 
PRC2 include maintenance of pluripotent programs throughout embryonic stem cell 
differentiation (Shen et al. 2008; Guenther et al. 2010) and establishment of bivalent or 
poised chromatin states that resolve throughout development (Bernstein et al. 2006; Cui 
et al. 2009; Lesch et al. 2013). Likewise, extensive work has demonstrated the 
requirement for PRC2-mediated H3K27me3 in extraembryonic development (Wang et 
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al. 2002b), X chromosome inactivation (Wang et al. 2001; Kalantry et al. 2006; 
Calabrese et al. 2012), spermatogenesis (Mu et al. 2014, 2017) (Aloia et al. 2013; 
Schuettengruber et al. 2017).  
H3K27me3 has also been studied in pathological contexts. In cancer, the 
methyltransferase EZH2 harbors several common mutations which lead to global 
changes in H3K27me3 levels (Yap et al. 2011; Ryan et al. 2011; Souroullas et al. 2016). 
In B cell lymphoma and melanoma, for example, a subset of tumors harbor mutations in 
EZH2 rendering the methyltransferase activity of EZH2 hyperactive, leading to 
increased H3K27me3 globally (Ryan et al. 2011; Souroullas et al. 2016). Interestingly, 
although there is a global increase in H3K27me3 in cells harboring mutations in EZH2, 
subsets of targets undergo H3K27me3 redistribution leading to locus-specific reductions 
in H3K27me3. The change in H3K27me3 distribution, particularly reduction at targets 
typically repressed by high levels of H3K27me3, leads to activation of oncogenes as 
opposed to homeostatic H3K27me3-mediated suppression (Souroullas et al. 2016).  
Inhibition of EZH2 in the context of these mutations holds promise as a 
therapeutic approach (Knutson et al. 2013, 2014; Xu et al. 2015). Cell lines, xenografts, 
and genetically engineered mouse models demonstrate reductions in cell or tumor 
growth following treatment with EZH2 inhibitors in the context of the mutations (Knutson 
et al. 2013; Xu et al. 2015; Souroullas et al. 2016). Additionally, Souroullas et al. 
demonstrated that concomitant treatment of EZH2 mutant melanomas with EZH2 
inhibitors and BRD4 inhibitors yielded remarkable tumor regression (Souroullas et al. 
2016). These results suggest that redistribution of H3K27me3 in the context of EZH2 
mutation leads to aberrant HAT activity and H3K27ac. If so, then the results from 
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Souroullas et al. implicate H3K27me3 and H3K27ac antagonism in the context of 
tumorigenic aberrations that is consistent with other reports of antagonism between the 
opposing modifications.   
Beyond mutations to the machinery that deposits modifications to histones, 
indirect effects on histone modifications have been the subject of recent investigation. In 
diffuse pontine gliomas, a rare form of pediatric brain tumor that arises in the brainstem, 
PRC2 trimethylation activity is silenced by mutations that occur in its substrate, histone 
3 (Weinberg et al. 2017). The mutation leads to a lysine-to-methionine substitution 
(termed H3K27M) that renders the levels of H3K27me3 to be globally reduced. 
Interestingly, in DIPG and in other contexts when PRC2 is perturbed there is a 
subsequent increase in H3K27ac (Lewis et al. 2013; Mohammad et al. 2017), consistent 
with a model for antagonism between H3K27me3 and H3K27ac. These results indicate 
that in H3 wild-type cells, H3K27me3 deposited by PRC2 prevents H3K27ac from 
accumulating and aberrantly activating proto-oncogene PRC2 target genes. Loss of 
PRC2 trimethylation activity leads to H3K27ac deposition by unveiling chromatin targets 
that would otherwise be unavailable to HAT machinery. Intersection of chromatin 
machinery in developmental and pathological contexts unlocks new opportunities to 
study the dynamic relationships between chromatin regulators and chromatin signals.  
  
Erasers 
Erasers are the enzymes that remove post-translational modifications. These 
enzymes are diverse and exhibit substrate specificity in order to control gene 
expression programs with accuracy (Seto and Yoshida 2014; Lalonde et al. 2014). 
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Many erasers can be classified into large families of related proteins with unique, 
comparable functions aside from the residues for which they display affinity (Lalonde et 
al. 2014). Like other chromatin modifiers, many erasers exist in large multimeric 
complexes that contain accessory proteins with histone recognition domains, conferring 
additional specificity to sets of genomic targets (Lalonde et al. 2014). Importantly, 
erasers often function at the junction between repressive and active chromatin states 
because they act to remove a modification in order to allow an opposing modification to 
be deposited. 
Histone deacetylases (HDACs) are among the most well-studied erasers. 
HDACs remove the acetylation deposited by HATs like CBP and P300 (Shi and Mello 
1998). Additional evidence suggests HDACs and HATs participate in an oppositional 
interplay (Pelletier et al. 2000; Shahbazian and Grunstein 2007; Johnsson et al. 2009). 
This serves several purposes. One clear function is to work in conjunction with 
repressive writer enzymes such as PRC2 to establish or maintain repressive chromatin 
at critical cellular junctures. For example, EZH2 physically interacts with HDAC4 (Caretti 
et al. 2004) indicating the two proteins function coordinately to repress chromatin. 
Similarly, in the context of pathology, combined inhibition of EZH2 and HDACs yields 
synergistic effects in tumors that overexpress EZH2 (Takashina et al. 2016). These 
results are consistent with a coordinated role for EZH2 methyltransferase activity and 
histone deacetylation. HDAC activity has also been shown to be required for EZH2 
function (Kleer et al. 2003; Cao et al. 2008) where HDAC inhibition abrogates EZH2 
hyperactivity as a treatment (Cao et al. 2011). In addition, HDACs may function 
homeostatically across the genome to either prevent unwanted activating chromatin 
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signals from accumulating at their targets or by counteracting transient HAT function at 
inactive targets (Wang et al. 2009). 
A separate function by HDACs may be in resetting chromatin states following 
transcription (Wang et al. 2002a, 2009; Shahbazian and Grunstein 2007). Early reports 
of HDACs uniformly supported repressive roles for the modifiers (Kadosh and Struhl 
1997; Rundlett et al. 1998; Vogelauer et al. 2000; Wu et al. 2001). However, genomics 
approaches indicated that HATs and HDACs co-localize across the genome and are 
correlated with high levels of gene expression (Wang et al. 2009), similar to an early, 
unexpected report (Wang et al. 2002a). Additional investigation resolved some of the 
debate. It appears evident that HDACs perform two functions in chromatin regulation. 
One function serves to reset excessive accumulation of acetylation in active regions, 
therefore conserving cellular and metabolic machinery (Wang et al. 2009). A second 
function is in repressive regions, likely in conjunction with writers of repressive 
modifications like PRC2, to prevent pervasive transcription. Both roles require similar 
capabilities from erasers, however the cohort of co-regulatory machinery appears to be 
distinct (Wang et al. 2009), indicating the activity of a single protein or protein complex 
is likely determined, at least in part, by the other proteins associated with a locus.  
Interestingly, HDACs are not required for organismal development, although 
tissue-specific phenotypes occur in mice lacking HDACs (Haberland et al. 2009). The 
lack of strong organismal-wide phenotypes in HDAC-mutant organisms may be the 
result of the diversity and scale of additional HDACs that potentially possess the ability 
to compensate for loss of function of one (Haberland et al. 2009). Indeed, investigation 
of HDACs has revealed both redundant and distinct functions (Dovey et al. 2010; 
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Haberland et al. 2010; Jurkin et al. 2011; Lin et al. 2012) suggesting that context-
specific cues may determine whether HDACs compensate for one another.  
The initial discovery of an HDAC (Taunton et al. 1996) closely coincided with the 
discovery of the HAT GCN5, discussed earlier (Brownell et al. 1996). The concomitant 
discoveries helped launch the field of epigenetics given the newfound identification of 
counteracting chromatin regulators. In the decades since the seminal discoveries, 
crosstalk between acetylation and methylation of histones has emerged as one of most 
exciting fields in chromatin biology (Fischle et al. 2003; Lee et al. 2010).  
In addition to HDACs, another example of an eraser that plays a critical role 
mediating the transition between active and repressive chromatin states are histone 
demethylases. In 2007, a series of discoveries catalogued the demethylase function of 
Jumonji C (JmjC) domain containing proteins UTX and JMJD3 (De Santa et al. 2007; 
Agger et al. 2007; Lan et al. 2007; Lee et al. 2007). These proteins function in an 
oxidation-dependent manner, and are highly conserved across the animal kingdom 
(Klose et al. 2006), indicating the role of histone demethylation is critical to an array of 
biological systems. Specifically, UTX and JMJD3 serve to recognize and remove 
H3K27me3, potentially enabling H3K27 acetyltransferases such as CBP and P300 to 
function (Petruk et al. 2013), although this mechanism has not been fully described. If 
true, sets of loci regulated by an H3K27 demethylase are converted from repressive to 
active states in a CBP or P300-dependent manner. Additional evidence corroborates 
such a model. A recent paper indicates that the demethylase UTX functions in junction 
with P300 to activate enhancers (Wang et al. 2017). Loss of UTX abrogates the 
acetylation of P300-target enhancers, suggesting that UTX and P300 function in a 
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coordinated manner (Wang et al. 2017). The authors demonstrated that UTX physically 
interacts with P300 and additional activation machinery to do so (Wang et al. 2017).  
Considering EZH1/2 methylates H3K27 to repress chromatin and that UTX and 
P300 function coordinately to activate chromatin, a cyclical mechanism for H3K27 
modification is appealing (Fig. 1.2). Current evidence suggest that in order to activate 
an EZH1/2-methylated enhancer, UTX-mediated demethylation and concomitant or 
sequential P300-mediated acetylation occurs. It is likely that yet more chromatin-related 
machinery may be necessary to facilitate the transition from inactive to active chromatin 




Figure 1.2. Model Depicting Transition between Active and Repressive Chromatin 
States. Histone deacetylases and histone methyltransferases have been shown to 
function coordinately to repress chromatin regions. Histone demethylases and histone 
acetyltransferases serve the opposite function. It is necessary to explore the role of 
additional types chromatin regulators in mediating these transitions in order to clarify the 





One additional class of chromatin regulator that has been appreciated to serve a 
critical function in chromatin signaling cannot be classified as a reader, writer, or eraser. 
This class conducts a biological role that is unique and shown to be essential for animal 
and tissue development, gene regulation, DNA damage repair, and tumorigenesis 
(Clapier and Cairns 2009; Clapier et al. 2017). They are ATP-dependent chromatin 
remodeling enzymes. These enzymes are multi-subunit molecular machines that 
mobilize nucleosomes by breaking histone-DNA contacts using ATP hydrolysis.  
As opposed to readers, writers, and erasers which generally act by targeting 
specific residues within an exposed histone tail, ATP-dependent chromatin remodeling 
enzymes target entire nucleosomes, and even series of nucleosomes, as their 
substrate. In addition, they are highly abundant. It has been predicted that one ATP-
dependent chromatin remodeling enzyme exists per 10 nucleosomes in a cell (Längst 
and Manelyte 2015). In addition, they can contain up to 15 protein subunits that are 
present in variable stoichiometry and in some cases, composition (Clapier and Cairns 
2009; Clapier et al. 2017). Given their roles in nucleosome targeting and regulation, we 
refer to this class of regulator as “movers”.1 
 Generally, there are four families of movers: Switch/sucrose non-fermentable 
(SWI/SNF), Imitation switch (ISWI), Chromodomain helicase DNA-binding (CHD), and 
INO80. It has been proposed that the ability to translocate DNA unifies the complexes 
across families (Clapier et al. 2017), and indeed, movers are unique in their capacity to 
remodel the location of nucleosomes within the genome. If DNA translocation is the 
                                               
1 Elsewhere (See Chapter 2, Chapter 3), we have also referred to this class of 
chromatin regulator as “remodelers” however we will not use that terminology in this 
chapter.  
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central theme for movers, then the accessory proteins within the large multimeric mover 
machines likely determine the precise function of a mover. The INO80 Complex (INO80-
C) of the INO80 mover family, for example, contains 15 unique proteins that based on 
structural data may contain as many as six copies of hallmark proteins within a single 
INO80-C (Tosi et al. 2013; Watanabe et al. 2015). Additionally, the SWI/SNF family of 
movers exhibits a notorious array of compositions and variations (Hodges et al. 2016). 
Variations in composition in the SWI/SNF family is thought to confer cell-type and locus 
specific functionality (Raab et al. 2015; Hodges et al. 2016; Alpsoy and Dykhuizen 
2018).   
Similar to the existence of four discrete families of movers, there are 
distinguishing functions of complexes within each family. Clapier et al. proposed that 
three distinct chromatin outcomes are possible following the activity of a mover: 
nucleosome assembly, chromatin accessibility, and nucleosome editing (Clapier et al. 
2017). Nucleosome assembly refers to the the ability of ISWI and CHD family movers to 
assemble histone proteins to form a nucleosome, in contrast to so-called nucleosome 
editing which is conducted by the INO80 family and results in the insertion or removal of 
canonical histone proteins with variant histones that possess variable histone-DNA 
contact strength. The SWI/SNF family mediates chromatin accessibility by repositioning 
nucleosomes along the chromatin fiber or ejecting and evicting nucleosomes from a 
given genomic location. INO80-C has also demonstrated this function (Clapier et al. 
2017).  Additionally, several movers contain accessory proteins that combine chromatin 
regulatory roles such as the NuRD complex of the CHD family which contains multiple 
HDACs (HDAC1, HDAC2, HDAC3, HDAC8) (Denslow and Wade 2007).  
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The array of outcomes for nucleosomes targeted by movers and the variety of 
subfamilies and subcomplexes within a single mover family underscores the critical and 
multipart function that the complexes play in facilitating chromatin state. Nonetheless, 
regulation of mover activity and the identification of how movers identify target sites is 
largely unknown. For example, numerous studies have shown that movers bind widely 
across the genome (Euskirchen et al. 2011; Yen et al. 2012, 2013; Raab et al. 2015, 
2017; de Dieuleveult et al. 2016) despite the locus specificity that their accessory 
subunits presumably provide (Runge et al. 2016) and the identification of specific 
phenotypes from developmental studies investigating their distinct biological roles (Hota 
and Bruneau 2016).  
The question ought to be raised whether movers exhibit a somewhat non-specific 
binding pattern because their enzymatic activity is tightly regulated. Given the fact that 
movers regulate thousands of genes with varying potency (Raab et al. 2015, 2017) it is 
likely that local cues determine the function of movers at sets of sites genome-wide. 
Moreover, it is likely that local chromatin state plays a role in recruiting or opposing the 
activity of movers through their accessory subunits. In future work, exploring whether 
movers are required for transitions between chromatin states (Fig. 1.2) is critical to 
elucidating the details of chromatin regulation and transcription. 
  
Rationale for Investigating Chromatin-based Crosstalk by Movers 
Recent insights indicate that movers contribute to a surprising array of critical 
functions in cell and organismal biology through chromatin remodeling activities. 
Consistent with biochemical studies that detail the in vitro abilities of movers (Clapier 
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and Cairns 2009; Clapier et al. 2017), in vivo studies provide insight into the 
physiological output of mover function (Kadoch and Crabtree 2015; Hota and Bruneau 
2016). Nonetheless, the existing mechanistic data introduce a paradox. Movers bind 
widely across the genome (Euskirchen et al. 2011; Yen et al. 2012, 2013; Raab et al. 
2015, 2017; de Dieuleveult et al. 2016), and conduct their enzymatic activity when 
bound to substrate nucleosomes (Clapier and Cairns 2009). Does the output of movers 
vary based on genomic locus or is it unilaterally the same at all of its chromatin-bound 
targets? Transcriptional evidence suggests that a unilateral function for a given mover is 
unlikely (Raab et al. 2015, 2017). For example, when members of the SWI/SNF mover 
are genetically perturbed, widespread changes in gene expression result (Raab et al. 
2015, 2017). Additionally, the gene expression changes are consistent with the mover 
possessing unique functions at different sets of genomic sites (Raab et al. 2015, 2017).  
Strong evidence suggests variations in mover composition may allow for diverse 
functions for a single mover. The SWI/SNF mover undergoes a composition switch in 
the developing brain of mice, for example (Ho et al. 2009b; Vogel-Ciernia et al. 2013). 
The protein BAF53A is a core SWI/SNF subunit in mouse embryonic stem cells that 
becomes is substituted by a related protein BAF53B upon neural differentiation (Ho et 
al. 2009b). The subunit switch is required for successful differentiation and upon loss of 
BAF53B, neural deficiencies emerge (Vogel-Ciernia et al. 2013). Similarly, in synovial 
sarcoma a different SWI/SNF subunit, SS18, undergoes a fusion event with the 
transcription factor SSX to create a mutant SWI/SNF that relocalizes genome-wide and 
promotes tumorigenic gene expression programs (Kadoch and Crabtree 2013). These 
data suggest that mover function and mover composition are highly plastic in vivo.  
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Underscoring the importance of clarifying the role of movers in chromatin-based 
crosstalk is a recent link between the BAF SWI/SNF mover and a histone 
methyltransferase named PRC1. Work completed by Stanton et al. suggests that the 
BAF SWI/SNF mover opposes PRC1, but when the BAF ATPase SMARCA4 undergoes 
mutation in cancer, the BAF opposition is lost and PRC1 activity subsequently 
accumulates at BAF-regulated targets (Stanton et al. 2017). Additionally, PRC1 activity 
recruits PRC2 (Blackledge et al. 2014), yielding H3K27me3 to suppress targets that are 
active in SMARCA4 wild-type cells (Stanton et al. 2017). This evidence supports a 
model that the output of mover activity is dependent on locus-specific and mover 
composition-specific cues. The model for BAF-PRC1 antagonism has been extended to 
the underlying mechanism in synovial sarcoma (Kadoch et al. 2017). In synovial 
sarcoma, SS18-SSX fusion protein is incorporated into SWI/SNF, mutant SWI/SNF 
retargets genome-wide, opposing PRC1 and in turn, antagonizes PRC2 mediated target 
repression. At its de novo targets in synovial sarcoma, the mutant SWI/SNF evicts 
PRC1 from its resident locations in order to promote tumorigenic programs (Kadoch et 
al. 2017). These data demonstrate that the relationship between movers, readers, 
writers, and erasers is likely more robust than currently appreciated. 
This thesis is focused on the INO80-C mover, which was not known to exhibit 
any compositional heterogeneity at the time the project began. In the years since, 
including the work completed in this thesis, the INO80-C mover has been demonstrated 
to engage in a more diverse network of protein associates than previous biochemical 
analyses of its composition suggested (Xue et al. 2017; Runge et al. 2018). As this 
thesis will describe in detail, the variations in its composition and interacting associates 
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direct the function of the INO80-C mover. Moreover, based on the evidence in the 
literature and this thesis, INO80-C is now considered unlikely to exhibit a unilateral 
function in chromatin regulation. Locus-specific cues and variable protein associates are 
likely directly involved in determining its function at specific genomic sites. This 
observation is important because it appears that other chromatin regulators, described 
above, operate similarly. Because movers are required for development, disease, and 
basic cellular functions, understanding both their contribution and the principles of their 
function are critical to refining our understanding of chromatin biology and the histone 
code hypothesis.  
 
Figure 1.3. Questions in INO80-C Biology. INO80-C has recently received a flurry of 
interest from the scientific community, largely because it possesses the unique ability to 
exchange variant histones that comprise nucleosomes. However, the role that local 
histone PTMs play in recruiting INO80-C and if readers, writers, and erasers function in 




Other Chromatin Signals 
Before concluding this introduction, it is paramount to acknowledge, briefly, the 
other factors that influence chromatin regulation that are beyond the scope of this 
thesis. Firstly, DNA sequence has been shown to impact nucleosome affinity at 
genomic locations in yeast, flies, and chickens (Lee et al. 2004; Segal et al. 2006). 
These data and others suggest that genetic structures such as promoters are generally 
unlikely to house nucleosomes due to frequent A-T dinucleotides or an 
underrepresentation of G-C dinucleotides (Iyer 2012).  Other evidence suggests that 
perhaps only a subset of DNA sequences are positioned by intrinsic sequences 
(Peckham et al. 2007; Iyer 2012). In either case, DNA content may account for inter-
organismal differences in nucleosome position and gene expression, but intra-
organismal differences are likely conducted by epigenomic and transcriptional 
machinery as genomic content is largely conserved. 
DNA itself can be modified, most famously by cytosine methylation (Jeltsch and 
Jurkowska 2014). Cytosine methylation is repressive (Plongthongkum et al. 2014) and 
inhibits the recruitment of machinery that activates transcription (Nan et al. 1998; Jones 
et al. 1998). Numerous insights have revealed that cytosine methylation may also 
serves as a template for more complex DNA modifications, including oxidation of 
methylated CpG sites by ten-eleven translocation (TET) enzymes in a TCA cycle 
metabolite-dependent manner (Kohli and Zhang 2013). The intersection of metabolic 
processes and chromatin regulation is a common, albeit complicated, issue subject to 
immense scientific interest (Lu and Thompson 2012).  
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One intersection between chromatin, genomic location, and metabolism are 
topologically-associated domains (TADs). TADs are long-range chromatin interactions 
that form insulated genomic regions (Dekker and Heard 2015). Facilitated by cohesin 
and transcription factor CTCF, TADs demonstrate the 3-dimensional nature of 
chromatin within the nucleus and the dependency on metabolic homeostasis for 
physiologic integrity. Interestingly, the binding of cohesin and CTCF is sequence-
specific and abrogated by DNA methylation (Bell and Felsenfeld 2000; Wang et al. 
2012). Additionally, mutation of Isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) in 
gliomas has been shown to yield an oncometabolite that perturbs the function of DNA 
demethylases, leading to inappropriately methylated CpGs and aberrant cohesin and 
CTCF binding (Flavahan et al. 2016). Subsequently, TADs are redistributed genome-
wide causing transcriptional machinery to constitutively activate the glioma oncogene 
PDGFRA (Flavahan et al. 2016).  
Finally, post-translational modifications and non-coding RNAs are strongly 
associated with the function of chromatin regulators, in some cases they drive 
chromatin-state entirely (Plath et al. 2002). Post-translational modification to 
transcription factors is a widely studied phenomenon with numerous examples of 
modifications permitting or prohibiting transcription factor function (Filtz et al. 2014). 
Among readers, writers, erasers, and movers, the list is similarly expansive. For 
example, P300 has been shown to autoacetylate itself in a manner that stimulates its 
catalytic activity at target histones (Thompson et al. 2004). Additionally, the NOTCH-
responsive factor MAML1 potentiates P300 autoacetylation, effectively driving NOTCH-
mediated transcriptional programs through P300-mediated H3K27ac following 
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extracellular NOTCH stimulation (Hansson et al. 2009). Autoacetylation of P300 is 
tightly regulated. Black et al. demonstrated that the histone deacetylase SIRT2 
diminishes P300 catalytic activity in opposition to P300 autoacetylation (Black et al. 
2008). This indicates that P300 catalytic activity can be both allosterically activated and 
suppressed. Postepska-Igielska et al. demonstrated that a long-noncoding RNA Khps1 
recruits P300 to the promoter of a nearby gene, stimulating activation of the gene and a 
related cellular program (Postepska-Igielska et al. 2015). At enhancers, CBP is subject 
to regulation by non-coding RNAs. Bose et al. showed that CBP interacts with 
enhancer-specific bi-directional non-coding RNAs (eRNAs) that recruit or sequester 
CBP to stimulate H3K27ac (Bose et al. 2017). These studies demonstrate the array of 
factors that regulate the activity of HATs and likely other regulators. 
Movers are similarly subject to allosteric regulation, although the examples are 
few in number. For one, INO80-C is phosphorylated to stimulate its role in DNA damage 
response (Morrison et al. 2007). INO80-C is also subject to a cycle of ubiquitination and 
de-ubiquitination in order to stabilize replication forks and promote genome stability (Lee 
et al. 2014a). Other movers ISWI and the NuRD complex can be acetylated (Ferreira et 
al. 2007). SWI/SNF subunit BAF155 is subject to methylation in breast cancer where 
methylated BAF155 promotes metastasis by re-targeting the SWI/SNF complex to 
promoters of genes involved in oncogenic pathways (Wang et al. 2014b). Over time, it is 
likely other examples of post-translational modifications to movers will emerge in the 
literature. As the new details regulating the function and activity of readers, writers, 
erasers, and movers emerge, the complexity of the chromatin-based networks that drive 
gene expression programs will increase exponentially.  
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The interconnectedness of chromatin regulatory pathways necessitates the 
investigation of how multivalent chromatin signals are transmitted and interpreted by the 
four classes of chromatin regulators. Doing so will elucidate details into a complex 
component of cell biology that has implications for physiology and pathophysiology. 
Exploring whether the four classes and movers in particular contribute to additional 
chromatin-related machinery in homeostasis and disease, such as metabolism and 
TADs, is likely to be an area of great interest.  
In summary, the genome is comprised of numerous forms of regulatory 
information that is critical to physiology. Aberrant interpretation or implementation of this 
complex information potentiates disease through chromatin-mediated mechanisms. As 
made clear by the references above, readers, writers, erasers, movers, DNA sequence 
and methylation, TADs, cellular metabolism, and allosteric regulation are critical 
components to proper chromatin regulation. The common thread among these many 
factors is the interrelation of their function and readout. The theme of interrelated 
function, or crosstalk, between chromatin regulators is paramount to uncovering the 
precise output of the elaborate array of known and unknown chromatin signals.
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CHAPTER 2: HYPOTHESES FOR CROSSTALK BETWEEN MOVERS2 
 
Overview 
Cells utilize precise mechanisms to access genomic DNA with spatiotemporal 
accuracy. ATP-dependent chromatin-remodeling enzymes (also known simply as 
“remodelers”) comprise a specialized class of enzymes that is intimately involved in 
genomic organization and accessibility. Remodelers selectively position nucleosomes to 
either alleviate chromatin compaction or achieve genomic condensation locally, based 
on a multitude of cellular signals. By dictating nucleosome position, remodelers control 
local euchromatin and heterochromatin states. These activities govern the accessibility 
of regulatory regions like promoters and enhancers to transcription factors, RNA 
polymerases, and coactivators or -repressors. As studies unravel the complexities of 
epigenetic topography, evidence points to a chromatin-based interactome where 
regulators interact competitively, cooperatively, and/or codependently through physical 
and functional means. These types of interactions, or crosstalk, between remodelers 
raise important questions for tissue development. Here, we briefly review the evidence 
for remodeler interactions and argue for additional studies examining crosstalk.
                                               
2 Portions of this chapter were adapted from Runge, J. S., J. R. Raab, and T. 
Magnuson, 2016 Chapter One - Epigenetic Regulation by ATP-Dependent Chromatin-
Remodeling Enzymes: SNF-ing Out Crosstalk, pp. 1–13 in Current Topics in 
Developmental Biology, edited by Paul M. Wassarman. Academic Press. 
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Introduction 
The hypothesis that the epigenome contains a readable language of DNA 
methylation, post-translational modifications to unstructured histone tails, and multi-
dimensional chromatin boundary elements has dramatically improved the understanding 
of chromatin regulation by stimulating careful analysis of previously unappreciated 
epigenetic details (Strahl and Allis 2000). Regulation of gene subsets by epigenetic 
features can dictate cellular transitions (i.e. proliferation, potency, differentiation) and 
drive de novo tissue development with distinct epigenomic signatures (Roadmap 
Epigenomics Consortium et al. 2015). Within the context of the epigenome, remodelers 
have emerged as critical regulators of developmental programs (Clapier and Cairns 
2009). 
There are four major subfamilies of remodelers (SWI/SNF, INO80, ISWI, and 
CHD). All are considered derivatives of the SNF2 ATPase family (Fig. 2.1). Each 
remodeling complex contains a single catalytic ATPase that utilizes ATP hydrolysis to 
achieve the energy-intensive modulation of chromatin (Fig. 2.1, parentheses). Notably, 
several remodelers utilize multiple ATPases via mutually exclusive relationships (Fig. 
2.1; SWI/SNF, NURD). Mutual exclusivity is not limited to the ATPase subunit, as each 
remodeling family contains several positions within the complex that can be filled by 
mutually exclusive proteins. Additionally, remodelers can utilize the same accessory 
subunits even across family and subfamily classifications (Fig. 2.1). The fact that 
remodeler components form distinct biochemical complexes on the basis of ATPase 
inclusion and accessory subunit incorporation is one of the most intriguing topics in 
remodeler biology. The compositional similarities between remodelers may implicate the 
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complexes in direct relationships via cooperative or competitive means. Likewise, it is 
probable that variation in composition between remodelers is indicative of functional 
heterogeneity across remodeler subfamilies. However, limited knowledge on the 
biological functionality, locus-specific assembly, and regulatory crosstalk of remodelers 
exists to date. These topics are of central importance to the biomedical community 
given the broad implications for understanding gene regulation through epigenetic 
mechanisms. 
 
Figure 2.1. SNF2 ATPase Chromatin-Remodeling Enzymes. Representative diagram 
of ATP-dependent chromatin-remodeling families. Families are designated by white 
boxes. Specific remodelers are represented as circles. Catalytic ATPases for each 
remodeling complex are indicated in parentheses. Subunits that incorporate into 
multiple complexes are identified by curved lines. Notably, the ISWI family includes 
additional complexes not depicted here (NoRC, RSF, WICH). 
 
Remodeler ATPases are engines to the nuclear machines. They are archetypal 
subunits around which each remodeling complex is assembled, and are evolutionarily 
conserved across eukaryotes indicating their essential contribution to life. They 
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hydrolyze hundreds of ATP molecules per minute to facilitate nucleosome sliding, 
histone variant exchange, and promoter clearance on a genome-wide scale (Holstege 
et al. 1998). They also contain additional functional domains that direct their function. 
For example, the predominant ATPase-containing subunit of SWI/SNF, BRG1 (encoded 
by the SMARCA4 gene in humans), contains a carboxy-terminal bromodomain that 
targets acetylated lysines on exposed histone tails, thereby promoting activation of 
transcription (Dutta et al. 2014). As each remodeler ATPase contains an essential SNF2 
ATPase domain as well as conserved domains that promote specific activities of the 
remodelers, they are the subject of intense investigation. 
In addition to the ATPase, each complex also contains multiple protein subunits 
that facilitate the assembly and action of each remodeling machine. The BPTF subunit 
of the NURF complex in the ISWI subfamily, for example, deposits trimethylation on 
lysine 4 residues of histone 3 (H3K4me3), a hallmark of chromatin priming that 
establishes local euchromatin and recruits transcriptional activators (Guenther et al. 
2007). Deposition of H3K4me3 allows the NURF complex to dramatically alter the 
chromatin state of specific targets through both chromatin remodeling and post-
translational modification of histones (Wysocka et al. 2006). This bridging of chromatin 
remodeling and chromatin modifying activities is common in chromatin remodeling 
complexes. In comparison to the H3K4me3 deposition by the NURF complex, the 
NURD Complex in the CHD subfamily contains multiple histone deacetylases (HDAC1, 
HDAC2, HDAC3, HDAC8) that enable the complex to deacetylate histone tails and 
compact nucleosome arrays (Denslow and Wade 2007). The counteracting activities of 
the NURF and NURD Complexes are representative of differing functions between 
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remodelers as well as the importance of non-ATPase subunits in directing remodeler 
function. The canonical compositions and activities of each remodeler subfamily have 
been reviewed extensively and biochemically-derived maps of complex-members have 
been defined (Conaway and Conaway 2009; Bartholomew 2014; Gerhold et al. 2015; 
Koster et al. 2015; Kadoch and Crabtree 2015). Yet we still know surprisingly little about 
the biological function of many proteins that co-purify with the complexes. Because 
each remodeler contains numerous accessory subunits that have undefined biological 
roles and it is likely that each confers a functional advantage to the complex(es) they 
associate with, we project that current knowledge on remodeler compositions and 
interactions underestimates the diversity of activities within remodeler-class epigenetic 
regulation in vivo. 
New evidence indicates remodelers co-localize to a large proportion of the 
mammalian genome and directly compete or cooperate (Morris et al. 2014). Studies on 
remodeler co-dependencies indicate remodelers may antagonize one another for 
promoter occupancy and locus control in yeast and mammals (Parnell et al. 2015), 
similar to the counteracting remodeling exhibited by the NURF and NURD complexes. 
Additionally, extensive studies have revealed unexpected stochasticity in non-canonical 
assemblies of remodeler components in developmental and pathological contexts 
(Sawa et al. 2000; de la Serna et al. 2001; Lickert et al. 2004; Lessard et al. 2007; 
Staahl et al. 2013). To gain a comprehensive understanding of remodeler-class 
regulatory activities, it is necessary to examine current data that implicate remodelers in 
an interdependent and dynamic network genome-wide. As we learn more about the 
abundance and significance of interactions between remodelers, the consequences for 
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gene regulation, cell differentiation, and tissue development are immense. Such 
functional crosstalk between remodelers is the focus of this essay. 
  
Remodeler Localization Genome-wide 
Despite longstanding evidence from genetic experiments that remodelers 
perform specific functions throughout the genome (Bultman et al. 2000; Hargreaves and 
Crabtree 2011) there are new indications that remodelers engage in dynamic functional 
interactions. This unexpected result has shaped recent outlooks on chromatin biology in 
development by challenging biochemically-derived molecular structures and predictions 
on remodeler functionality. These insights reveal genomic crosstalk occurs on an 
unprecedented scale. 
Extensive work has identified that the SWI/SNF complex localizes to active 
genomic elements (Ho et al. 2009a; Euskirchen et al. 2011). In one particular study, 
multiple subunits of the SWI/SNF complex were mapped genome-wide (Euskirchen et 
al. 2011). In addition, all interactions associated with the SWI/SNF complex were 
analyzed by mass spectrometry. Together, these data showed the full genome-wide 
and proteome-wide interactions carried out by the canonical SWI/SNF complex. While 
this work provides a valuable baseline for the genomic occupancy and the interacting 
partners of the SWI/SNF complex, variable subunits within the complex have not been 
mapped. Future work analyzing the various biochemically distinct forms of SWI/SNF 
and other chromatin remodeling complexes is needed to understand the functional and 
phenotypic diversity of these remodelers. 
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The localization of SWI/SNF components to regulatory positions throughout the 
genome aligned with previous findings that targeted mutations in remodelers cause 
dramatic phenotypes. Murine embryos lacking the Brg1 subunit of SWI/SNF fail to 
complete the perimplantation stage of development, for example (Bultman et al. 2000). 
However, investigations of remodelers from different families have confounded the 
assumption that mutagenic phenotypes arise in part by unique genomic localization. 
ChIP paired with high-throughouput sequencing (ChIP-seq) for the catalytic subunits of 
SWI/SNF, ISWI, and CHD subfamilies revealed that these distantly related remodelers 
co-localize across the genome with a high frequency (Morris et al. 2014). Intriguingly, 
disruption of the complexes led to unique chromatin organization phenotypes according 
to nucleosome mapping techniques. Therefore despite co-localization, remodelers 
perform non-redundant roles in regulating genomic packaging. The regulation of this 
activity does not appear to be at the level of genomic occupancy, leaving a major 
unanswered question of how remodelers that bind similar regions and presumably 
modulate overlapping genes sets exhibit different phenotypes. Resolution of DNA 
binding by remodelers may obscure interpretations given the inability to accurately 
distinguish subtle variations using current technologies. One exciting alternative is that 
remodelers engage with local epigenetic cues after binding chromatin, resulting in 
dynamic regulation of remodelers despite similar targeting preferences. 
One interesting scenario to evaluate crosstalk between remodelers would be to 
test the regulatory activities of closely-related complexes. Examining the genomic 
localization preferences and gene expression control by complexes that are 
biochemically-similar would clarify the biological functionality of biochemically-discrete 
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remodelers. For example, the ARID1A and ARID2 subunits of SWI/SNF do not 
simultaneously appear in biochemical extractions of the SWI/SNF complex in vitro (Nie 
et al. 2000). Each ARID (AT-rich interacting domain) associates with discrete 
configurations of SWI/SNF, known as BAF (ARID1A) and PBAF (ARID2), and is 
required for promoter targeting by the intact complex (Chandler et al. 2013). It is likely 
that ARID1A and ARID2 target discrete loci to facilitate unique cellular programs for the 
two SWI/SNF configurations. However, given the co-occupancy of genomic sites by 
remodelers from different families it is possible that ARID1A and ARID2 containing 
complexes also co-occupy binding sites. ARID1A and ARID2 may target the same loci 
at different times, utilizing SWI/SNF subunits to target similar features but unique ARID 
subunits to achieve different regulatory results. We hypothesize that given their 
overlapping, yet distinct subunit compositions, BAF and PBAF exhibit both competition 
and cooperation with one another in their function as regulators of gene expression (Fig. 
2.2). 
 
Figure 2.2. SWI/SNF Interactions Genome-wide. Putative functional interactions 
between SWI/SNF subcomplexes. Illustrations demonstrate competitive or cooperative 
 36 
genomic binding and gene regulation by SWI/SNF complexes that share regulatory 
components. 
Currently, genomic co-localization by remodelers is best attributed to transient 
interactions at sites of nucleosome-depleted chromatin (Nagaich et al. 2004; Euskirchen 
et al. 2011; Morris et al. 2014). We propose that co-localization may serve a more 
specific purpose. Subunit-sharing between independent remodeling complexes could 
contribute to genomic targeting preferences by remodelers, where chromatin targeting 
by remodelers is dependent on direct cooperativity between counteracting or co-acting 
remodelers. Moreover, we predict that observed co-localization reflects that remodelers 
conduct separate regulatory functions throughout the genome and therefore allows cells 
to personalize their expression profiles based on local stimuli and epigenetic cues. 
  
Accessory Subunits in Remodeler Activities 
Given the mutual exclusivity of some remodeler factors and the similar 
localization patterns of evolutionarily divergent remodelers, the most elusive feature of 
remodelers to-date pertains to their functional composition in vivo. From glycerol 
gradient purifications and mass-spectrometry, each complex has been stringently 
purified to identify stable associates. SWI/SNF subfamily members are comprised of 8-
15 subunits, INO80 subfamily members have up to 18 subunits, while ISWI and CHD 
have fewer ranging between 3-4 and 1-11 subunits, respectively (Clapier and Cairns 
2009). Identifying if and when functional variations of these canonical complex 
compositions exist in vivo has been more challenging. 
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In addition to compositional heterogeneity, some remodelers like the INO80 and 
SWR complexes exhibit structural modularity (Watanabe et al. 2015). Each complex 
exists in two states, one elongated form and a compressed form. Presumably, these 
different forms represent captured states of the complexes mid-remodeling, in 
accordance with the “hinge” hypothesis where the remodeler stretches to target the 
nucleosome then bends to embrace and mobilize it (Tosi et al. 2013; Watanabe et al. 
2015). The extent of structural modularity within remodeler families is not known, 
despite several crystal structures that indicate nucleosome targeting is a predominant 
feature of remodeling complexes (Grüne et al. 2003; Dürr et al. 2006; Hauk et al. 2010; 
Kasten et al. 2011). Likewise, there is currently limited knowledge on the functionality of 
biochemically-defined complexes. High-resolution genomic mapping of SWR and INO80 
complexes in yeast identified nucleosomal targeting preferences of 20 subunits from the 
two complexes in total (Yen et al. 2013). But each complex has been typically studied 
from the perspective of only one or two subunits in functional settings, leaving many of 
the accessory subunits with limited characterization. The gap in our understanding of 
the functional assemblage of complexes, particularly in higher eukaryotes or single 
cells, has left the roles of the accessory subunits largely undefined. 
Several studies have recently provided intriguing hypotheses on the utility of 
lesser-known subunits. One well-supported hypothesis is that unique combinations of 
SWI/SNF subunits create distinct complexes, each with a different functional role. 
Namely, the degree of heterogeneity within SWI/SNF suggests accessory subunits 
perform essential and diverse functions. For example, SWI/SNF factor BAF53A 
(encoded by ACTL6A in humans) is replaced by BAF53B (encoded by ACTL6B) upon 
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differentiation of neuronal progenitors to neurons in mammals (Lessard et al. 2007). The 
subunit “switch” is essential for cells to complete cell lineage specification. Genetic 
mutations in BAF53B lead mice to acquire defects in synaptic plasticity and long-term 
memory suggesting BAF53B is systematically essential for the activities of mature 
neurons (Vogel-Ciernia et al. 2013). Similar phenotypes have been observed in 
hematopoietic and embryonic tissue types where constitutive BAF53A expression is 
required for repopulating cells but insufficient for differentiation (Krasteva et al. 2012; Lu 
et al. 2015).  
Identifying the activities of accessory subunits could be key to unlocking 
remodeler specification in vivo. In several developmental systems, evidence suggests 
specific SWI/SNF assemblies drive cell lineage choices in development (Sawa et al. 
2000; Lickert et al. 2004; Ho et al. 2009a, 2009b; Staahl et al. 2013) or cell lineage 
abandonment in malignancy (Kadoch and Crabtree 2013). This evidence implicates 
accessory subunits as central players in remodeling activities. In development, subunit-
exchanges by discrete remodelers are dictated by expression. The mechanism is likely 
more complex in cancer where remodeler components are ubiquitously expressed. 
Mutations in a single complex member likely allow chromatin remodeling activity by 
other forms of the complex in ways the are important for tumor formation and cancer 
proliferation. To understand physiology and pathophysiology, the roles of subunits that 
exist in multiple remodeling complexes and families should be clarified. We advocate for 
common subunits to be extensively characterized in order to clarify their role in 
remodeler-class crosstalk. 
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Intriguingly, BAF53A stably associates with many SNF2 remodelers. SWI/SNF, 
INO80, TIP60, and SRCAP Complexes all contain BAF53A as a core subunit (Kadoch 
and Crabtree 2015). Therefore assigning developmental phenotypes to any single 
BAF53A-containing remodeler is problematic because genetic manipulation of BAF53A 
would affect numerous activities of the other remodelers. Notably, BAF53A has been 
extensively studied in the context of the INO80 Complex. In vitro, BAF53A has been 
shown to be required for efficient DNA-dependent ATPase activity, histone targeting, 
and nucleosome mobility of the INO80 Complex (Chen et al. 2011, 2013). In addition, 
BAF53A forms a distinct structural module within the INO80 Complex composed of β-
actin and the actin-related protein ACTR8. This module has a high affinity for the 
helicase-SANT-associated (HSA) domain within the INO80 ATPase indicative of a 
stable and evolutionarily conserved interaction (Szerlong et al. 2008). SWI/SNF ATPase 
BRG1 also contains an HSA domain with BAF53A preference. Loss of either BAF53A 
alone or the BAF53A-β-actin-ACTR8 module is not required for the remodeling activities 
of the INO80 Complex, but greatly enhances them (Szerlong et al. 2008; Chen et al. 
2011). Therefore it is likely that BAF53A acts in concert with the additional remodeler 
subunits to maximize the biological efficiency for nucleosome eviction and placement, 
perhaps by increasing the targeting efficiency of the complex to specific epigenetic 
features where remodeling is necessary. In such a scenario, the subunit “switch” to 
BAF53B may facilitate a different targeting preference for SWI/SNF thereby enabling 
expression of differentiation-specific genes (Fig. 2.3). Little is known regarding the 
protein domains within BAF53A but clarification of its ability to be modified structurally or 
functionally may provide insight into its incorporation into specific remodeling complexes 
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and its preference for histone epitopes. While the exact functions for BAF53A in the 
other SNF2 remodelers have not been clarified, it is probable that BAF53A serves a 
unifying feature among BAF53A-containing SNF2 remodelers that makes them 
functionally cooperative and competitive. 
 
Figure 2.3. Role of Accessory Subunits in Remodeler Localization. Predicted 
remodeler localization preferences based on subunit composition. We hypothesize that 
BAF53A-containing complexes utilize the histone-binding subunit to target similar 
epigenetic features. Similarly, we hypothesize that subunit switching from BAF53A to 
BAF53B in SWI/SNF in cell lineage specification serves to relocalize SWI/SNF to sites 
that require expression at specific cell lineage timepoints. 
 
Other subunits are shared between remodelers. The helicases RUVBL1 and 
RUVBL2 (RUVBLs) exist in INO80, TIP60, and SRCAP yet their remodeling-related 
functions are largely unknown, due in part to the fact that the RUVBLs promiscuously 
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participate in non-remodeling activities through the Fanconi Anemia complex (Rajendra 
et al. 2014) and in snoRNP assembly (Bizarro et al. 2014). Assembly of INO80 and 
TIP60 has been shown to be dependent on the RUVBLs (Jónsson et al. 2004; Jha et al. 
2013). In addition, RUVBLs enhance the DNA binding ability of YY1, a transcription 
factor that canonically associates with INO80 (López-Perrote et al. 2014). This evidence 
suggests that the RUVBL proteins are required members of remodeler assemblies that 
exist to enhance binding efficiency and specification at epigenetic docking sites, similar 
to BAF53A. As with BAF53A, understanding the recruitment and action of accessory 
subunits like the RUVBLs within remodeling assemblies will be essential to clarifying 
their precise function in the context of chromatin remodeling and gene regulation. 
Recent data on remodeler interactions, cooperation, and functional heterogeneity 
of remodeling complexes suggest there is likely a diversity of remodeler compositions in 
vivo. Emerging genome-wide studies of remodeler assemblies will improve our 
understanding of the range of functional compositions that remodelers form. We 
anticipate that intra-family and inter-complex variation exists to provide cells maximal 
plasticity to regulate gene expression rapidly and effectively. Biochemical purifications 
of remodelers inform our understanding of remodeler compositions, and are informative 
at the cell population level. However, at an individual locus and a single point of time, 
the combinatorial assembly of proteins from a diverse set of subunits may yield unique 
function on a locus-specific scale. Highlighting the different functions of unique 
compositions of chromatin remodeling complexes will be key to understanding the many 




Faithful regulation of chromatin allows cells to maintain control over nucleosome 
position and gene expression. Because remodelers intimately interact with the genome 
to participate in chromatin regulation, their study is essential to understanding the 
dynamic epigenetic landscape as it pertains to genomic organization, integrity, and 
gene expression. As we currently understand only a fraction of the complexity that 
exists to modulate the epigenomic landscape in vivo, the study of remodelers, their 
interactions, and their components will provide important steps to clarify emergent 
questions of genomic regulation. The critical role of these complexes in development 
and disease highlight the necessity of understanding crosstalk within, and between, 
chromatin remodeling families.
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CHAPTER 3: IDENTIFICATION OF TWO DISTINCT CLASSES OF THE HUMAN 
INO80 COMPLEX GENOME-WIDE3 
 
Overview 
Chromatin remodeling and histone modifying enzymes play a critical role in 
shaping the regulatory output of a cell. Although much is known about these classes of 
proteins, identifying the mechanisms by which they coordinate gene expression 
programs remains an exciting topic of investigation. One factor that may contribute to 
the targeting and activity of chromatin regulators is local chromatin landscape. We 
leveraged genomic approaches and publically-available datasets to characterize the 
chromatin landscape at targets of the human INO80 chromatin remodeling complex 
(INO80-C). Our data revealed two classes of INO80-C targets with distinct chromatin 
signatures. The predominant INO80-C class was enriched for open chromatin, 
H3K27ac, and representative subunits from each of the three INO80-C modules 
(RUVBL1, RUVBL2, MCRS1, YY1). We named this class Canonical INO80. Notably, we 
identified an unexpected class of INO80-C targets that contained only the INO80 
ATPase and harbored a repressive chromatin signature characterized by inaccessible 
chromatin, H3K27me3, and the methyltransferase EZH2. We named this class Non-
                                               
3 Portions of this Chapter were adapted from Runge J.S.*, J.R. Raab*, and T. 
Magnuson. 2018. Identification of Two Distinct Classes of the Human INO80 Complex 
Genome-wide. G3: Genes, Genomes, Genetics. G3.300504.2017. 
*These authors contributed equally 
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Canonical INO80 (NC-INO80). Biochemical approaches indicated that INO80-C and the 
H3K27 acetyltransferase P300 physically interact, suggesting INO80-C and P300 may 
jointly coordinate chromatin accessibility at Canonical INO80 sites. No interaction was 
detected between INO80-C and EZH2, indicating INO80-C and EZH2 may engage in a 
separate form of regulatory crosstalk at NC-INO80 targets. Our data indicate that 
INO80-C is more compositionally heterogenous at its genomic targets than anticipated. 
Moreover, our data suggest there is an important link between INO80-C and histone 




ATP-dependent chromatin remodeling complexes (remodelers) comprise a class 
of highly conserved protein complexes that mediate nucleosome position throughout the 
genome (Clapier and Cairns 2009). Each remodeling complex contains a catalytic 
ATPase that breaks histone-DNA contacts using ATP hydrolysis and often includes 
additional proteins that facilitate nucleosome targeting and mobilization (Clapier and 
Cairns 2009; Runge et al. 2016). Much is known regarding the composition and 
molecular capabilities of remodelers, yet the factors regulating the function of 
remodelers at genomic targets remain elusive. Because remodelers dictate the position 
of nucleosomes and in turn the regulatory output of epigenomic loci, understanding the 
factors that contribute to the targeting and local function of remodelers is a key aspect in 
chromatin regulation.  
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To approach the question of how the localization and function of remodelers are 
influenced by local chromatin architecture, we elected to study the human INO80 
Complex (INO80-C). Details regarding the structural and biochemical assembly of 
INO80-C in vitro are well understood. Originally identified in a genetic screen for S. 
cerevisiae mutants sensitive to inositol (Ebbert et al. 1999), the catalytic ATPase of 
INO80-C, named INO80, was subsequently purified in a large complex that interacted 
with chromatin, hydrolyzed ATP, and mobilized nucleosomes in yeast (Shen et al. 
2000). Crystal and electron microscopy structures of the yeast INO80-C recapitulated its 
nucleosome-targeting function (Tosi et al. 2013; Watanabe et al. 2015). Additionally, 
yeast INO80-C subunits have been shown to stimulate or facilitate nucleosome 
targeting and ATPase activity in vitro (Jónsson et al. 2004; Chambers et al. 2012; 
Watanabe et al. 2015; Yao et al. 2016; Willhoft et al. 2016). Loss of these proteins 
confers sensitivity to metabolic stress, polyploidy, and reduces cellular fitness 
(Chambers et al. 2012; Yao et al. 2016; Gowans et al. 2018). Interestingly, INO80-C 
subunits may pre-assemble before integrating into the complex (Yao et al. 2016; Zhou 
et al. 2017). 
 
The INO80 protein serves as a scaffold for the rest of the complex in human cells 
(Chen et al. 2011), in agreement with how INO80-C is thought to assemble in yeast 
(Gerhold and Gasser 2014). Three sets of subunits form distinct modules through 
interaction with specific regions of the human INO80 protein (Chen et al. 2011) (Fig. 
3.1A). There are 15 mammalian constituents in total that comprise INO80-C (Jin et al. 
2005; Chen et al. 2011). Two modules (Module 1 and Module 2, Fig. 3.1A) are critical 
 46 
for INO80 hydrolytic and remodeling activities, where mutants lacking the modules 
render INO80-C unable to hydrolyze ATP, and recognize or slide nucleosomes in vitro  
(Cai et al. 2007; Chen et al. 2011, 2013). A third module (Module 3) is considered 
dispensable for these functions in vitro but contains DNA-binding and protein-modifying 
proteins potentiating an auxiliary function (Yao et al. 2008; Chen et al. 2011, 2013). 
These data suggest that the INO80 ATPase is more than the molecular engine for 
INO80-C. Instead, INO80 likely serves as a docking site for its subunits in a manner that 
is critical to its identification of suitable genomic targets and local remodeling function. 
We hypothesized that INO80 responds to site-specific chromatin-based regulatory cues 
that determine its function. To address this question we undertook a comprehensive 
characterization of INO80-C in human cells to identify putative relationships between 
chromatin signals and INO80-C function.  
 
Results 
Identification of a Distinct INO80 Binding Class Devoid of Canonical Subunits 
To investigate the factors that influence INO80-C function throughout the 
genome, we performed ChIP-seq for 4 subunits of INO80-C in the liver cancer cell line 
HepG2. We obtained data for a fifth subunit in HepG2, YY1, from ENCODE ((ENCODE 
Project Consortium 2012) GEO accession ENCFF000PSE, ENCFF000PSD). Together, 
the five subunits we mapped are representative of the three modules that form INO80-C 
(Fig. 3.1A) (Chen et al. 2011). Our ChIP-seq experiments showed that human INO80-C 
subunits localized to genomic elements at a similar ratio to one another, consistent with 
a unified function (Fig. 3.1B). The majority of binding sites were found proximal to the 
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promoter, with a large fraction of peaks (~40%) associated with distal or intronic 
regions. YY1 bound genomic elements at a moderately different proportion than INO80, 
RUVBL1, RUVBL2, and MCRS1, consistent with its known promiscuity as a DNA-
binding regulatory partner for several other complexes (Gordon et al. 2006). 
Additionally, the INO80-C subunits were markedly enriched around transcription start 
sites (TSS) of highly expressed genes (Fig. 3.1C). Interestingly, the subunits were not 
enriched at transcription end sites (TES) (Fig. 3.1C), despite evidence that INO80-C 
binds both TSSs and TESs in yeast (Xue et al. 2015, 2017). This observation suggests 
that nucleosome depletion near the transcription end site does not depend on INO80-C 
in human cells (Fan et al. 2010). Such an organism-specific distinction is consistent with 
organismal differences in genome organization and the identification of mammalian 
specific INO80-C subunits that are not present in other eukaryotes (Jin et al. 2005).  
 
We were surprised to find that 22% of INO80 ATPase peaks did not overlap 
RUVBL1, RUVBL2, MCRS1, or YY1 (Fig. 1D, E). We separated INO80 ChIP-seq peaks 
into two categories to analyze this unexpected group further. The first category, named 
Canonical INO80, refers to sites where the INO80 ATPase displayed co-occurrent 
peaks with any other protein we mapped (RUVBL1, RUVBL2, MCRS1, and YY1). The 
second category, named Non-Canonical INO80 (NC-INO80), contains only the INO80 
peaks that displayed no overlap with peaks of other INO80-C subunits. To determine 
the genome-wide enrichment of INO80-C subunits in the two categories, we measured 
signal for INO80, RUVBL1, RUVBL2, MCRS1, and YY1 in both (Fig. 3.1E). INO80 itself 
displayed high signal in both categories (Fig. 3.1E) indicating that the two groups are 
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robust INO80 targets. Although the other subunits exhibited high signal at Canonical 
INO80 sites genome-wide as expected, they showed very low ChIP-seq signal at NC-
INO80 sites (Fig.3.1E). The two categories of INO80 targeting also exhibited different 
widths for INO80 enrichment at the peak summit (Supp Fig. 1A). Given the role of 
INO80 as a scaffold for its biochemical partners, we hypothesized that the NC-INO80 





Figure 3.1. Genomic Occupancy of INO80-C Members Reveals Two Distinct Types 
of Sites. A. Schematic of INO80 protein and locations of binding modules, proteins 
mapped by ChIP-seq are highlighted in red. B. Genomic distribution of INO80-C 
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members. C. ChIP-seq signal of INO80-C subunits aligned relative to gene units (-1.5kb 
upstream to +1kb downstream). Rows are ordered based on expression of all 
expressed genes in HepG2 cells (n = 17157). D. ChIP-seq signal example of Canonical 
INO80 and NC-INO80 sites. E. Metagene plots of signal for INO80 and 4 others 
mapped INO80-C subunits aligned to midpoint of NC-INO80 and Canonical INO80 sites 
(n = 4949 NC-INO80, n = 18716 Canonical).  
 
NC-INO80 Class Harbors Heterochromatin Signature 
Biochemical evidence suggests the remodeling activity of INO80-C is most 
efficient when its subunit modules are intact. Therefore we measured chromatin 
accessibility at Canonical INO80 and NC-INO80 sites using ENCODE DNase-seq data 
in HepG2. Canonical INO80 sites displayed high signal by DNase-seq (Fig. 3.2A). 
Because INO80-C binding is associated with highly expressed genes (Fig. 3.1), these 
data support a model where INO80-C mobilizes nucleosomes to facilitate chromatin 
accessibility. In contrast, DNase-seq signal at NC-INO80 sites was low (Fig. 3.2A) 
suggesting INO80 is not able to facilitate chromatin accessibility at these sites.  
 
To identify distinguishing chromatin features that influence INO80 targeting, we 
intersected our ChIP-seq datasets with chromatin state predictions from ENCODE in 
HepG2 (ChromHMM (Ernst et al. 2011)). We found that Canonical INO80 and NC-
INO80 targets were enriched for distinct chromatin states (Fig. 3.2B). More than 70% of 
Canonical INO80 targets overlapped chromatin states representing highly active 
chromatin, including states associated with active promoters and strong enhancers. 
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Alternatively, the majority of NC-INO80 targets (65%) were co-localized with repressive 
chromatin states. Only a very small fraction of NC-INO80 peaks resembled active 
promoters. Approximately 20% of both INO80 classes were enriched for states 
associated with weak promoters and strong enhancers. In addition, we analyzed 
ENCODE ChIP-seq datasets in HepG2 to investigate specific co-regulatory candidates 
that may influence INO80 function at the two classes. Notably, the EZH2 
methyltransferase from the Polycomb Repressive Complex 2 (PRC2) and the primary 
post-translational modification it deposits on lysine 27 of histone 3 (H3K27me3) were 
highly enriched at NC-INO80 sites, whereas signal for EZH2 and H3K27me3 were 
markedly lower at Canonical INO80 sites (Fig. 3.2C). Moreover, the opposing 
modification on lysine 27 of histone 3 (H3K27ac) was absent from NC-INO80 sites but 
highly enriched at the Canonical INO80 class (Fig. 3.2C). These data suggest 
Canonical INO80 and NC-INO80 targets represent functionally different regulatory 
elements. While Canonical INO80 interacts with active genomic elements and co-
localizes with H3K27ac, NC-INO80 is strongly enriched for heterochromatin features 
including PRC2 and H3K27me3.  
 52 
 
Figure 3.2. Characterization of Chromatin Features at Canonical and Non-
Canonical INO80 Sites. DNase signal at each class of peaks generated using 
ENCODE Data (GEO accession ENCSR149XIL). B. Fraction of INO80 peaks from each 
class that are localized to different types of ChromHMM states (Ernst et al. 2011). C. 
Metaplots centered on Canonical INO80 and NC-INO80 sites for EZH2, H3K27me3, 
and H3K27ac. Data were generated by ENCODE (GEO accessions ENCSR000ARI 
(EZH2), ENCSR000AOL (H3K27me3), ENCSR000AMO (H3K27ac)). 
 
Additionally, we used our previous RNA-seq data in HepG2 cells (Raab et al. 
2015) to determine the expression level of genes near Canonical INO80 and NC-INO80 
sites. We assigned genes to either Canonical INO80 or NC-INO80 based on the nearest 
 53 
INO80 ChIP-seq peak. Genes targeted by NC-INO80 were expressed at dramatically 
lower levels than genes targeted by Canonical INO80 (Fig. 3.3A). These data correlate 
with the repressive chromatin signature at NC-INO80 targets and implicate each class 
with its expected regulatory output based on local chromatin features.  
 
 
Figure 3.3. Expression of Genes near INO80 Targets Correlates with Local 
Chromatin State A. Gene expression in HepG2 of genes assigned by linear distance to 
INO80 peaks. Genes with assignments to peaks of both Canonical INO80 and NC-
INO80 peaks were excluded.  
 
Biochemical Evidence of INO80-C Crosstalk with Histone Modifying Enzymes 
We next performed a series of biochemical experiments to determine if INO80-C 
interacted with histone modifiers of the chromatin landscape from Canonical INO80 and 
NC-INO80 classes. First, we performed low-stringency co-immunoprecipitations to 
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determine if INO80-C members interacted with PRC2. Although we detected robust 
interactions between members of the same complex, we did not detect any interaction 
between the INO80 ATPase and EZH2, or other members from opposite complexes 
(Fig. 3.4A).  
 
Surprisingly, we observed interactions between members of INO80-C and P300 
by co-immunoprecipitation under the same conditions (Fig. 3.4B). P300 is a histone 
acetyltransferase that deposits acetylation on H3K27 and is known to be antagonized 
by H3K27me3 from PRC2 (Pasini et al. 2010). Interestingly, although P300 
immunoprecipitation yielded the INO80 ATPase and subunits of INO80-C, we did not 
detect reciprocal interactions between P300 and the INO80 ATPase so we utilized an 
orthologous approach to validate the interaction. We performed glycerol gradient 
sedimentation to determine if P300 and the INO80 ATPase migrated in overlapping 
fractions, which would suggest they exist in a similarly-sized protein complex and 
indicates a physical interaction between them likely occurs. Indeed, P300 and the 
INO80 ATPase displayed overlap, distinct from EZH2 (Fig. 3.4C). Importantly, P300 
displayed a bimodal distribution where P300 was abundant in low glycerol 
concentrations suggesting an INO80-independent P300 likely exists. These data 
implicate INO80-C remodeling capabilities with the acetyltransferase activity of P300 but 




Figure 3.4. INO80 Interacts with the Histone Acetyltransferase P300. 
A, B. Immunoprecipitation for INO80 and EZH2 followed by western blotting for 
members of each complex. C. Western blots performed on fractions of glycerol gradient 
sedimentation in HepG2 cells. 
 
Discussion 
Our data suggest that two remarkably distinct classes of INO80-C targeting exist 
in human cells (Fig. 3.5). A class we named Canonical INO80 contained a histone 
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modification signature consistent with active chromatin states (DNase sensitivity, 
H3K27ac) and was occupied by all the INO80-C subunits we mapped. The second 
class was marked by repressive chromatin features (DNase insensitivity, EZH2 and 
H3K27me3) and surprisingly lacked the INO80-C accessory subunits RUVBL1, 
RUVBL2, MCRS1, and YY1. We named this second class Non-Canonical INO80 (NC-
INO80). Genes near Canonical INO80 exhibited high levels of expression, whereas 
genes near NC-INO80 were lowly expressed. We identified that INO80-C physically 
interacted with P300 under endogenous conditions, suggesting INO80-C and P300 
coordinate chromatin accessibility jointly at Canonical INO80 sites. We did not detect 
interactions between INO80-C and PRC2 indicating that either these two complexes do 
not physically interact at NC-INO80 sites or that they may interact through non-physical 
means (antagonistic, sequential, mutually exclusive) that our genomics and biochemical 
approaches are unable to resolve. Given the stark differences in epigenomic signatures 
at the two classes of targets, these results suggest that local chromatin landscape is 
important to INO80-C targeting and function. 
 
 
Figure 3.5. Two Distinct Classes of INO80-C Binding Genome-wide. A. Model 
illustrating the distinguishing characteristics of Canonical INO80 and NC-INO80 binding 
in HepG2 cells. 
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Our discovery that NC-INO80 correlates with inaccessible chromatin suggests 
that the INO80 ATPase binds widely across the genome, and that the appropriate 
chromatin context may determine the ability of INO80-C to assemble and remodel 
chromatin. This is consistent with a scaffolding function for the INO80 protein and its 
requirement for interaction with its accessory subunits to mobilize nucleosomes 
(Jónsson et al. 2004; Chen et al. 2011, 2013; Watanabe et al. 2015; Yao et al. 2016; 
Willhoft et al. 2016).  
 
Zhou et al. recently proposed that in vivo assembly of INO80-C occurs in a 
stepwise fashion, which may explain the differences in subunit localization and 
chromatin features at Canonical INO80 and NC-INO80 targets (Zhou et al. 2017). The 
authors demonstrated that conserved INO80-C constituents RUVBL1 and RUVBL2 form 
a heterohexamer independently from INO80-C in yeast. Recognition of the INO80 
ATPase by the RUVBL1-RUVBL2 hexamer and co-stimulation by ATP hydrolysis leads 
RUVBL1-RUVBL2 to facilitate complete INO80-C assembly and activity (Zhou et al. 
2017). The authors proposed that after the remodeling function of INO80-C is 
completed, RUVBL1-RUVBL2 are subsequently ejected from INO80-C, leading to 
disassembly of the complex, and recycling of RUVBL1-RUVBL2 as they await the 
appropriate signals to initiate and complete INO80-C assembly again. Similarly, INO80-
C subunits IES6 and ARP5 have been shown to form a subcomplex independently of 
INO80-C (Yao et al. 2016). The IES6-ARP5 subcomplex is critical for INO80-C 
remodeling activities, but lacks the ability to bind to or remodel nucleosomes on its own 
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(Yao et al. 2016). These findings and our own raise the possibility that there is a 
cascade of stepwise INO80-C assembly that occurs in vivo, generating incomplete 
formations of INO80-C throughout the genome that are unable to remodel chromatin. 
We speculate that local chromatin landscape may be a contributing factor that guides 
INO80-C assembly and function. 
 
Aside from a model for stepwise assembly of INO80-C in vivo, one alternative 
explanation could be that INO80-C forms an array of complexes and subcomplexes 
throughout the genome, with each comprised of distinct sets of proteins that facilitate 
specific functions. Similar remodeling complexes to INO80-C, such as SWI/SNF, have 
been shown to exhibit striking compositional plasticity (Hodges et al. 2016). Genomics 
studies have demonstrated that variable SWI/SNF subunits exert discrete functions at 
loci that are differentially occupied (Euskirchen et al. 2011; Raab et al. 2015, 2017). For 
SWI/SNF, it has been proposed that this variability indicates that cells may contain 
dozens or even hundreds of SWI/SNF compositions (Kadoch and Crabtree 2015). For 
INO80-C, there have been far fewer instances of heterogeneity described in the 
literature to date. Our data suggest that at least two types of INO80-C target chromatin 
in human cells. While there may be subsets of complexes throughout the genome that 
our classification strategy does not address or that variability in antibody efficiency 
prevents us from detecting, it seems possible INO80-C is not quite as variable as 
SWI/SNF and instead contains a few specific subtypes and formations.  
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For instance, Xue et al. recently demonstrated that the INO80 ATPase forms a 
complex with transcriptional modifiers MOT1 and NC2, termed MINC (Xue et al. 2017). 
MINC suppressed transcription at its targets in yeast and murine embryonic stem cells. 
MOT1 and NC2 had been shown to jointly suppress transcription by inhibiting the 
function of the transcriptional activator TBP (van Werven et al. 2008; Koster et al. 2014) 
suggesting MINC antagonizes gene activation. Importantly, a subset of MINC targets 
correlated with factors from the Polycomb Repressive Complex 1 and exhibited low 
levels of TBP. These sites closely resemble the NC-INO80 targets we describe.  
 
Interestingly, MINC also suppressed transcription at a set of targets that 
harbored active chromatin features (Xue et al. 2017). The localization of MINC to both 
active and repressive chromatin targets is consistent with our observations, although 
Canonical INO80 and NC-INO80 classes contain distinct INO80-C compositions. 
Perhaps MINC is a specialized variant of INO80-C, as other groups have demonstrated 
that INO80-C directs gene activation, as well as gene repression, in several contexts 
(Cai et al. 2007; Wang et al. 2014a; Yao et al. 2016; Zhou et al. 2016; Gowans et al. 
2018). In total, results from our group and others point to an impressive level of 
complexity for INO80-C in its targeting, molecular assembly, and functional output that 






Materials and Methods:  
Cell Culture 
HepG2 cells were purchased from the ATCC and grown in DMEM (Gibco, Life 
Technologies) supplemented with 10% Fetal Bovine Serum and penicillin/streptomycin 
(100 units/mL).  
 
Antibodies 
Antibodies used include the following: BAF53A: LifeSpan Biosciences LS-
C196606 (Western). EZH2: Millipore 07-400 (ChIP, IP, Western). INO80: Abcam 
ab105451 (ChIP, IP, Western). MCRS1: Proteintech 11362-1-AP (ChIP). RUVBL1: 
Bethyl A304-716A (ChIP) and Abcam ab51500 (Western). RUVBL2: Bethyl A302-537A 
(ChIP) and Abcam ab89942 (Western). SUZ12: Cell Signaling 3737S (Western). YY1: 




HepG2 cells were fixed using 0.3% formaldehyde in 1X PBS for 30 minutes at 
4°C. Fixative was quenched with 1/10 volume of 2M glycine for 5 minutes at room 
temperature. Cells were pelleted at 2000 rpm for 10 minutes at 4°C, then washed 3 
times by resuspension in 50mLs of ice cold 1X PBS and centrifugation at 2000 rpm for 





ChIP was performed as previously described (Raab et al. 2015). Briefly, prior to 
beginning the ChIP, we washed Dynal Protein A beads 3 times with PBS + 0.5% BSA at 
4°C. We resuspended beads in 400μL of 1X + 0.5% BSA, then added 4-10ug of 
antibody and incubated overnight at 4°C. The following day, we thawed the fixed cells 
for 30 minutes on ice. We then resuspended each pellet in 1mL swelling buffer (25mM 
HEPES + 1.5mM MgCl2 + 10mM KCl + 0.1% Igepal). We added 10mM PMSF and 
Proteinase Inhibitor Cocktail, and pooled the samples. The pooled samples were 
inverted for 10 minutes at 4°C then dounced 20 strokes. We pelleted nuclei at 2000 rpm 
for 7 minutes at 4°C. Nuclei were resuspended in 5mL Sucrose Buffer A (0.32M 
Sucrose, 15mM Hepes pH 7.9, 60mM KCl, 2mM EDTA, 0.5mM EGTA) + PMSF and 
Proteinase Inhibitor Cocktail. Then 5mL Sucrose Buffer B (30% Sucrose, 15mM Hepes 
pH 7.9, 2mM EDTA, 0.5mM EGTA) was gently added. We centrifuged the sucrose 
solution at 3000 rpm for 10 minutes at 4°C, then washed the pellet in 10mL MNase 
Digestion Buffer (15mM Hepes pH 7.9, 60mM KCl, 15mM NaCl, 0.32M Sucrose) at 
2000 rpm for 7 minutes at 4°C. The pellet was resuspended in 1mL MNase Digestion 
Buffer per 4e7 cells + 3.3μL 1M CaCl2 per mL + PMSF and Proteinase Inhibitor 
Cocktail, then incubated for 5 minutes at 37°C to warm. We added MNase at 0.5μL/1e7 
cells and incubated for 15 minutes at 37°C. Following digestion, the MNase was 
chelated using 1/10 volume 0.5M EDTA on ice for 5 minutes. We added 1 volume of 2X 
IP Buffer (20mM TrisCl pH 8, 200mM NaCl, 1mM EDTA, 0.5mM EGTA), then passed 
the sample for a 20G needle 5 times and a 25G needle 5 times. The sample was split 
into microcentrifuge tubes and centrifuged at 13,000 rpm for 15 minutes at 4°C to 
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remove debri. We pooled the supernatants and placed on ice for 1 hour. The pellets 
were resuspended in 1mL 1X IP Buffer (10mM Tris-HCl pH 8, 100mM NaCl, 1mM 
EDTA, 0.5mM EGTA) and inverted for 1 hour at 4°C. Then we centrifuged the sample 
and mixed the supernatant with S1. We added 1% Triton-X 100 to the chromatin. The 
sample was split evenly to the prepared beads, after they were washed twice with 1X 
PBS + 0.5% BSA and twice with 1X IP Buffer. We saved 10% of the sample for input 
and incubated the IPs overnight at 4°C. The following day we washed the beads 10 
times with Agilent RIPA wash by adding 1mL wash buffer and inverting for 4 minutes at 
4°C. Beads were subsequently washed one time with 1X TE + 50mM NaCl before 
elution at 65°C with agitation using 100μL 1% SDS + 100mM NaHCO3 made freshly. 
We removed the supernatant and treated with 5μL of 5M NaCl overnight to reverse the 
crosslinks. We cleared RNAs and proteins by adding 3μL RNaseA for 45 minutes at 
37°C and then Proteinase K for 2 hours at 56°C. Precipitates were purified using the 




Preparation of Nuclear Lysates 
Cells were washed with PBS, then centrifuged for at 1300 rpm for 10 min at 4°C. 
Cells were washed with 20 packed cell volumes with hypotonic cell lysis buffer (10mM 
HEPES-KOH pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT) plus protease inhibitors 
and placed on ice for 10 min to swell. Cells were then centrifuged at 1300 rpm for 10 
min at 4°C. Cells were dounced with 2 packed cell volumes of hypotonic cell lysis buffer. 
 63 
Nuclei were pelleted at 1300 rpm for 10min at 4°C. Nuclei were washed with 10 packed 
cell volumes with hypotonic cell lysis buffer and centrifuged at 5000 rpm for 10 min. 
Extractions were performed with 60μL of nuclear lysis buffer (20mM HEPES-KOH pH 
7.9, 25% glycerol, 420 mM KCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM and protease 
inhibitors) per 100μL cell pellet. Lysates were clarified at 14,000 rpm for 10 min at 4°C 
between extractions. Lysates were diluted with storage buffer (20mM HEPES-KOH pH 




Prior to beginning the IP, we washed Dynal Protein A beads 3 times with PBS + 
0.5% BSA at 4°C. We resuspended beads in 400μL of 1X + 0.5% BSA, then added 5μg 
of antibody and incubated overnight at 4°C. The following day, we thawed the nuclear 
lysates on ice. Lysates were added to antibody-conjugated beads and incubated 
overnight. Beads were washed 7 times for 5 minutes each, in this order: 2X with IP 
Buffer (20mM HEPES-KOH pH 7.9, 0.15M KCL, 10% glycerol, 0.2mM EDTA pH 8.0, 
0.1% Tween-20, 0.5mM DTT, and protease inhibitors), 3X with Wash Buffer (20mM 
HEPES-KOH pH 7.9, 0.1M KCL, 10% glycerol, 0.2mM EDTA pH 8.0, 0.1% Tween-20, 
0.5mM DTT, and protease inhibitors), and 2X Final Buffer (20mM HEPES-KOH, pH 7.9, 
60mM KCl, 10% glycerol, 0.5mM DTT, and protease inhibitors). Proteins were eluted 
from beads using 2X Laemmli buffer with 1:10 DTT for 10 minutes at 95°C. Beads were 
magnetized and supernatants stored at -20°C.  
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Glycerol Gradient Sedimentation 
Density sedimentation was performed as previously described (Kadoch and 
Crabtree 2013). Briefly, 500μg of HepG2 nuclear lysates were suspended in 0% 
glycerol HEMG buffer (25mM HEPES pH 7.9, 0.1mM EDTA, 12.5mM MgCl2, 100mM 
KCL, DTT and PMSF), loaded into a glycerol gradient (10mL 10-30% glycerol in 
HEMG), and centrifuged at 40K RPM for 16 hours at 4°C. 500μL fractions were 
collected, suspended in 2X Laemmli buffer with 1:10 DTT, and boiled for 5 minutes at 




Reads were aligned to hg19 using bowtie2 (Langmead and Salzberg 2012) using 
the --sensitive parameters, and duplicates were removed using samtools (Li et al. 
2009). For visualization bigwig tracks were generated using Deeptools (version 2.2.2) 
bamCoverage tool with a binsize of 10bp and extending fragments to the approximate 
nucleosome size of 150bp. Tracks can be visualized using IGV (Robinson et al. 2011) 
and bw files are available in GEO accession number GSE97411.  
 
Peak Calling 
Peaks were called using Macs2 (version 2.1.0 (Zhang et al. 2008)) using the 
narrowpeak mode using the following parameters. Qval = 0.001 --keep-dup-all --shift 37 
--nomodel --extsize 147. Additionally, we filtered the peaks against the ENCODE 
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blacklist regions and further recursively merged any peaks within 500bp of the nearest 
peak.  
 
Definition of Non-Canonical sites 
We defined Canonical INO80 and Non-Canonical INO80 sites using a simple 
overlap approach. We used the filtered and merged peak files generated above to 
define INO80 bound regions that did not have any overlap with any of the other INO80-
C subunit sites.  
 
Comparison with ENCODE Data  
Raw fastq files for YY1 were downloaded from the ENCODE project and 
processed as with other INO80-C subunits. H3K27ac, H3K27me3, and EZH2 data bam 
alignment files were downloaded and used to generate bigwig files as above. Coverage 
at regions of interest were generated using Deeptools (version 2.2.4 (Ramírez et al. 
2016) with the computeMatrix function using a binsize of 10bp using the bigwig files 
generated above. These were further processed using the heatmapper module of 
deeptools or using ggplot2 in R (version 3.2.2).    
  
RNA-seq Analysis 
For gene expression analysis, we used our previous RNA-seq data in HepG2 
cells (Raab et al. 2015). Expression analysis was carried out on single end 50bp reads. 
Gene expression levels were quantitated using kallisto (Bray et al. 2016). These data 
were converted to counts and summarized per gene using tximport (Soneson et al. 
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2015). When comparing genes associated with the two classes, we assigned genes to 
the nearest peak.  
 
Data Availability 
All raw and processed data are deposited under GEO accession number 
GSE97413. ChIP-seq data is deposited under series GSE97411. Processed peak calls 
for ChIP can be found in Supplemental Table 1.
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CHAPTER 4: EXPLORATION OF NC-INO80 FUNCTION USING GENETIC AND  
 
Introduction 
Based on evidence that INO80-C exhibits two distinct binding classes genome-
wide in HepG2 cells, we investigated the molecular contribution of INO80-C to 
chromatin state and gene expression at its targets. In particular, we were interested in 
the function of NC-INO80 given its status as an unexpected feature of INO80-C 
targeting. Notably, it was surprising that INO80-C and PRC2 components did not 
interact despite their co-localization at NC-INO80 sites in HepG2 (Chapter 3). Based on 
this evidence, we hypothesized that INO80-C and PRC2 engage in a separate form of 
regulatory crosstalk than the cooperativity traditionally assigned to co-localizing protein 
complexes. In this chapter, our efforts to clarify the relationship between INO80-C and 
PRC2 are described.  
 
Results 
We continually validated our INO80 antibody to confirm the quality our reagents. 
For instance, we treated HepG2 cells with siRNA and shRNA to INO80. In western blots 
on whole cell lysates of these cells we observed a decrease in INO80 proteins levels as 
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expected (Fig. 4.1A). Additionally, we fractionated HepG2 cells into chromatin, nuclear, 
and cytoplasmic components to confirm that the detected INO80 protein was chromatin 
bound (Fig. 4.1B). We performed endogenous immunoprecipitation to test for 
nonspecific bands from the INO80 antibody (Fig. 4.1C). We observed that the antibody 
was robust and specific (Fig. 4.1C). Prior evidence demonstrated that we were able to 
immunoprecipitate the established members of INO80-C using this antibody under the 
same conditions (Fig. 3.4). Given these data, we felt confident proceeding with 
additional experiments to study INO80-C using these reagents. 
 
Figure 4.1. Validation of INO80 Antibody. A. siRNA and shRNA were used to 
knockdown protein levels in HepG2 cells. shRNA were packaged into lentivirus prior to 
 69 
infection. B. HepG2 cells were separated into chromatin bound, nuclear soluble, and 
cytoplasmic compartments. H3 (chromatin fraction) and β-TUB (nuclear, cytoplasmic) 
served as loading controls. C. Immunoprecipitation experiments were performed on 
nuclear lysates prepared from HepG2 cells. 5% of the nuclear lysate was loaded as 
input. IgG IP served as a control for non-specific bands. Bar indicates INO80 protein 
band.  
First, we performed overexpression experiments to test if the INO80 ATPase and 
EZH2 physically interacted at a low level that was not detectable in our prior 
endogenous co-immunoprecipitation experiments. We overexpressed FLAG-tagged 
INO80 and HA-tagged EZH2 in 293T cells (Fig. 4.2). Overexpression of either protein 
did not yield an interaction. Interestingly, when both FLAG-INO80 and HA-EZH2 were 
overexpressed in these cells, we observed an interaction between the tagged proteins. 
Given that these experiments were conducted using tagged and overexpressed 
constructs, and that the introduction of either INO80 or EZH2 alone was not sufficient to 
generate a detectable interaction, the interaction we detected should be interpreted 
cautiously. Despite these caveats, we conclude that these results provide additional 
preliminary evidence that there may be meaningful biology between INO80-C and 
PRC2 at NC-INO80 sites.  
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Figure 4.2. Co-immunoprecipitation of Tagged and Over-expressed EZH2 and 
INO80 Proteins. A. FLAG or HA tagged proteins were expressed independently or in 
combination into 293T cells followed by cell lysis, immunoprecipitation, and western blot 
analysis.  
We next sought to expand our analysis of INO80-C localization and targeting in 
HepG2 cells to additional cell types. We analyzed data from other sources than our own 
laboratory to independently validate our observation of heterogeneity in INO80-C 
targeting. To identify which INO80-C subunits to consider, we determined which INO80-
C subunits were most representative of INO80-C binding. MCRS1 and YY1 accounted 
for the vast majority of INO80-C binding sites yielding a consistent number of NC-INO80 
sites when MCRS1 and YY1 peaks that overlapped INO80 peaks were removed from 
the NC-INO80 bin (Fig. 4.3). Of INO80-C subunits tested, including the SNF5 protein 
from SWI/SNF, overlapping either MCRS1 or YY1 with INO80 ChIP-seq peaks removed 
the largest proportion of putative NC-INO80 sites. In contrast, addition of RUVBL1 or 
RUVBL2 does not reduce the number of NC-INO80 targets called by peak calling 
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substantially. Likewise, MCRS1 and YY1 accounted for similar numbers of INO80 peaks 
(Fig. 4.3). We concluded that using MCRS1 or YY1 would suffice as a surrogate for 
INO80-C. Mapping additional proteins from the established INO80-C proteins and 
modules (RUVBL1, RUVBL2) offered no additional quantitative benefit to our 
categorization of Canonical INO80 and NC-INO80 targets. 
 
 
Figure 4.3. Number of NC-INO80 Peak Calls. INO80 ChIP-seq peaks in HepG2 cells 
were filtered against peak calls for other INO80-C subunits and the SWI/SNF subunit 
SNF5. A) Number of NC-INO80 Peaks after removing overlapping INO80 peaks and 
MCRS1 peaks first, followed by others. B) Number of NC-INO80 Peaks after removing 
overlapping INO80 peaks with YY1 peaks first, followed by others. These data indicate 
that ChIP-seq datasets for MCRS1 and YY1 are the most stringent datasets to compare 
versus INO80 peaks for identifying NC-INO80 peaks.  
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The only publicly available ChIP-seq datasets that included either MCRS1 or 
YY1 and the INO80 ATPase was the lung cancer cell line A549 (Zhou et al. 2016). We 
chose to use A549 for our independent validation of HepG2-identified Canonical INO80 
and NC-INO80 classes. Complementary datasets were generated by ENCODE and 
downloaded from publically available data repositories to use in conjunction 
(H3K27me3, H3K27ac, DNase-seq, RNA-seq). We found that a large portion of targets 
(~10%) bound by the INO80 ATPase lack the hallmark INO80-C accessory subunit YY1 
in agreement with our data for INO80-C localization in HepG2 (Fig. 4.4A). Strikingly, 
these sites were markedly enriched for H3K27me3 and devoid of signal for DNase-seq 
data, comparable to NC-INO80 targets in HepG2. Additionally, the Canonical INO80 
targets that contained peak overlap for both the INO80 ATPase and YY1 displayed high 
signal for H3K27ac and DNase-seq. These data indicated that Canonical INO80 and 
NC-INO80 categories are conserved across two human cell lines of divergent origin, 
and that our classifications of INO80-C binding were not an artifact of our ChIP-seq 
protocol or experimental handling. Moreover, genes near Canonical INO80 and NC-
INO80 targets in A549 cells correlated with the chromatin state predictions from HepG2. 
Canonical INO80 targeted loci near genes that were expressed at high levels whereas 
genes near NC-INO80 binding sites were lowly expressed (Fig. 4.4B). These data 




Figure 4.4. Publically Available ChIP-seq Datasets in A549 Cells Reveal NC-INO80 
Sites with Repressive Chromatin Features. A. Signal from ChIP-seq experiments 
was aligned at the midpoint of Canonical or NC-INO80 peaks (+/- 2kb). GEO 
accessions GSE82334 (INO80), ENCSR000BPM (YY1), ENCSR000AUI (H3K27ac), 
ENCSR000AUK (H3K27me3), ENCSR136DNA (DNase), ENCSR937WIG (RNA). B. 
Expression of genes that were assigned to either NC-INO80 or Canonical INO80 
classes based on linear distance to INO80 ChIP-seq peaks. Genes assigned to a peak 
in both classes were excluded. 
 
To test the generalizability of INO80-C heterogeneity in human cells, we selected 
a third cell line for additional analysis. We mapped INO80, MCRS1, RUVBL2, and YY1 
in the liver cancer cell line Huh7 using ChIP-seq. Again, these proteins represent the 
three modules of INO80-C which we included in these experiments for additional 
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experimental rigor (Fig. 3.1A). As in HepG2, INO80-C subunits were enriched at TSSs 
of highly expressed genes and absent from TESs (Fig. 4.5A). Importantly, we observed 
a class of INO80 ATPase targets that lacked hallmark INO80-C subunits from each of 
its modules in Huh7 cells, similar to HepG2. The fraction of NC-INO80 peaks was 
consistent between HepG2 and Huh7 (Fig. 4.5B). Approximately 20-25% of INO80 
targets lacked INO80-C subunits in both cell lines. Moreover, NC-INO80 targets in Huh7 
correlated with lower gene expression (Fig. 4.5C) and lower chromatin accessibility (Fig. 
4.5D, ENCODE DNaseI data) than Canonical INO80 targets, similar to HepG2. These 
data underscore our identification of a robust class of INO80 targets that lack INO80-C 




Figure 4.5. NC-INO80 Class is Present in Huh7 Cells. A. Canonical INO80 signal 
aligned at genes in Huh7 cells relative to gene unit (-1.5kb upstream and +1kb 
downstream). Genes are ordered based on expression in Huh7 cells. (GEO accession 
GSM2064293) B. Number of peaks in HepG2 and Huh7 assigned to Canonical INO80 
and NC-INO80 classes. C. Expression of genes assigned based on linear distance to 
either Canonical INO80 or NC-INO80 peaks. Genes assigned to a peak in both classes 
were excluded. D. DNase accessibility metaplots centered on midpoint of Huh7 INO80 
peaks for both Canonical and NC-INO80 sites. DNase data is from ENCODE (GEO 
accession ENCSR000EKD).  
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To gain insight into how INO80-C targeting varied between cell types, we next 
explored the dynamics of Canonical INO80 and NC-INO80 localization. Using two liver 
cancer cell lines for these analyses (HepG2 and Huh7) afforded us the opportunity to 
make comparisons across cell lines that share a similar physiology. We generated four 
categories of comparisons for the Canonical INO80 and NC-INO80 classes based on 
how localization of INO80-C subunits varied between cell lines: 1) Sites where 
Canonical INO80 or NC-INO80 peaks were detected in HepG2, but absent in Huh7. We 
named these “Lost”. 2) Sites where either Canonical INO80 or NC-INO80 peaks were 
detected at the same location in both cell lines. We named these “Conserved”. 3) Sites 
where HepG2 contained Canonical INO80 sites but harbored NC-INO80 in Huh7. We 
named these “Changed Canonical-NC”. 4) Sites where NC-INO80 sites in HepG2 were 
converted to Canonical INO80 in Huh7. We named these “Changed NC-Canonical.” By 
creating four classes (Lost, Conserved, Changed Canonical-NC, Changed NC-
Canonical) we generated tools to analyze INO80-C localization and heterogeneity for 




Figure 4.6. NC-INO80 Sites are Dynamic between Cell Types. A. Categorization of 
variation in HepG2 INO80 ATPase peaks when examined in Huh7 cells. HepG2 peaks 
were assigned to each category based on the presence or absence of either Canonical 
INO80 or NC-INO80 peak in Huh7. B. Representative loci for each class of dynamic 
INO80-C localization across HepG2 and Huh7.  
 
The vast majority of HepG2 NC-INO80 targets lacked an INO80 peak in Huh7. 
Similarly, approximately half of the HepG2 Canonical INO80 targets lacked a peak of 
INO80 or INO80-C subunits in Huh7. Therefore most sites of both Canonical and NC-
INO80 were categorized as Lost (Fig. 4.6A,B). Approximately 20% of NC-INO80 targets 
were Conserved between the cell types, whereas nearly 50% of Canonical INO80 
 78 
targets were Conserved (Fig. 4.6A,B). These data indicated that INO80-C targets 
chromatin in a cell-type specific manner. We compared the DNase accessibility at the 
different classes of sites using ENCODE data (Fig. 4.7). Consistent with changes in 
INO80-C subunit localization by ChIP-seq, we found HepG2 NC-INO80 sites that 
contained Canonical INO80 in Huh7 (Changed NC-Canonical) increased in chromatin 
accessibility, while those that lost INO80 targeting altogether (Lost-NC) became even 
less accessible than conserved NC-INO80 sites (Fig. 4.7). Similarly at Canonical INO80 
targets, sites that lost either accessory INO80-C subunits or the entire complex led to 
decreases in chromatin accessibility, while those sites with retained Canonical INO80 
(Conserved-Canonical) remained highly accessible (Fig. 4.7). Finally, we compared the 
ratio of expression in HepG2 and Huh7 cells at genes assigned to INO80-C targets in 
HepG2 cells (Fig. 4.7). Consistent with changes observed in both ChIP-seq and DNaseI 
accessibility, we found that genes regulated by INO80 that converted from NC-INO80 to 
Canonical INO80 sites (Changed NC-Canonical) were more highly expressed in Huh7 
relative to HepG2. Canonical sites that lost INO80-C (Lost Canonical-None or Changed 




Figure 4.7. Changes in INO80-C Localization are Associated with Chromatin and 
Gene Expression Changes. A. DNase sensitivity in Huh7 was measured at sites 
defined in panel Fig. 4.6. B. Relative expression between HepG2 and Huh7 using data 
from Raab et al (Raab et al. 2015) for HepG2 and GSM2064293 for Huh7 was 
calculated for genes assigned to each peak defined in Fig. 4.6. Data were quantile 
normalized and the log2 ratio of HepG2 over Huh7 is plotted. Box width reflects number 
of peaks within each group.  
 
Together, these data argue that changes in INO80-C targeting at specific 
genomic sites correlates with both chromatin structure and gene expression output. The 
variation in INO80-C targeting between the two cell lines indicates that localization of 
Canonical INO80 and NC-INO80 is likely dependent on or contributes to cell-type 
specific regulatory programs, including chromatin signaling. Given the cell-type specific 
distribution of NC-INO80 targets at repressed chromatin (Fig. 4.6), and that high DNase 
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sensitivity correlates with Canonical INO80 localization in a cell-type specific manner 
(Fig. 4.7), we hypothesized that heterochromatin signals prohibit INO80-C assembly. To 
investigate the interplay between INO80-C and heterochromatin signals, we performed 
a series of experiments to assess the relationship between INO80-C and PRC2.  
PRC2 binding and H3K27me3 are hallmarks of facultative heterochromatin 
(Montgomery et al. 2005; Simon and Kingston 2013) that characterize inaccessible 
chromatin, gene repression, and strongly correlate with NC-INO80 (Fig. 3.2, Fig. 4.4-
4.7.). Likewise, H3K27me3 is antagonized by H3K27ac (Tie et al. 2009; Pasini et al. 
2010) which characterizes Canonical INO80 (Fig. 3.2, Fig. 4.4-4.7). Therefore we 
utilized chromatin accessibility, H3K27 modifications, and gene expression as readouts 
for INO80-C activity.  
To gain insight into the role of INO80-C in regulating chromatin accessibility of its 
targets, we depleted the INO80 protein from HepG2 cells using two siRNAs and 
performed ATAC-seq (Fig. 4.8). Similar to ENCODE DNase-seq, ATAC-seq signal in 
cells treated with a non-targeting siRNA was enriched at peak summits of Canonical 
INO80 targets but depleted at NC-INO80 targets (Fig. 4.8B). We observed a decrease 
in chromatin accessibility at Canonical INO80 sites indicating INO80-C is critical for 
maintaining or establishing chromatin accessibility at sites where it assembles. 
However, chromatin accessibility at NC-INO80 targets was not sensitive to INO80 
depletion by ATAC-seq (Fig. 4.8B). The levels of chromatin accessibility at NC-INO80 
remained similar to background levels in the context of INO80 depletion. Therefore, at 
NC-INO80 targets the INO80 ATPase is not required for the maintenance of the 
repressed chromatin state. 
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Based on these data, it is possible that NC-INO80 sites represent a version of 
INO80-C that is unable to remodel chromatin given that they lack established INO80-C 
subunits previously shown to be required for INO80-C remodeling capabilities (Chen et 
al. 2011, 2013). Such a model would be consistent with biochemical data indicating 
assembly of INO80-C may occur in a stepwise fashion in vivo (Yao et al. 2016; Zhou et 
al. 2017), yielding incomplete and remodeling-incapable INO80-C subcomplexes. 
Activation of NC-INO80 targets may require the appropriate cascade of chromatin 
signaling events to occur. Moreover, the persistent chromatin inaccessibility at NC-
INO80 sites following depletion of INO80 protein from HepG2 cells contrasts with 
evidence in yeast and mouse ES cells that the INO80 protein participates in a 
suppressive complex with MOT1 and NC2 (MINC) at Polycomb-enriched chromatin 
(Xue et al. 2017).  
 
 
Figure 4.8. Perturbation of the INO80 ATPase Induces Non-Uniform Changes 
Chromatin Accessibility at INO80-C Targets.  A. Western blot of INO80 following 
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siRNA KD in HepG2 cells. B. ATAC-seq signal in NTG and siINO80#1 at INO80 peaks 
of both classes centered on midpoint of INO80 peak. 
 
 We next performed a series of bioinformatic techniques to categorize the two 
classes of INO80-C further, given that they exhibit disparate functional classifications 
and INO80-dependent chromatin accessibility phenotypes. Gene ontology analysis 
revealed that the gene sets targeted by NC-INO80 associated with developmental 
programs suggesting NC-INO80 sites include regions that are not necessary for 
homeostatic programs in these cells. Additionally, the strong developmental signature 
may implicate a putative biological function at these sites in developmental contexts 
(Fig. 4.9A), consistent with critical functions for INO80 in animal and tissue development 
(Min et al. 2013; Wang et al. 2014a; Serber et al. 2016; Qiu et al. 2016).  
We also identified separate sets of DNA motifs within each INO80-C class (Fig. 
4.9B). Notably, the known DNA binding motif for YY1 was the most highly enriched 
sequence within the Canonical INO80 sites substantiating our ChIP-seq datasets (Fig. 
4.9B). At NC-INO80 sites, we identified several known DNA binding motifs for MEF2 
family proteins that enhance transcription in myocyte lineages (MEF2C, MEF2B, 
MEF2A, Fig. 4.9B). Given the heterochromatin signature at NC-INO80 sites and the low 
levels of gene expression of nearby genes, MEF2 proteins are unlikely to be bound at 
these sites. Interestingly, MEF2 family proteins have been shown to function 
coordinately with P300 to activate targets (Sartorelli et al. 1997; Ma et al. 2005; Ryan et 
al. 2015) indicating that activation of NC-INO80 targets may require P300 and MEF2 
transcription factors. The dissimilarity between Canonical and NC-INO80 in these 
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bioinformatic analyses indicated the two classes have separate and distinct roles in 
chromatin regulation.  
 
 
Figure 4.9. GO and Motif analysis of Canonical INO80 and NC-INO80 Sites. A. 
Canonical INO80 and NC-INO80 sites were analyzed for over-represented GO terms in 
HepG2 cells. Color of the circle represent adjusted p.value, size of circle represents 
number of genes in the overlap. B. Homer analysis of motifs found at Canonical INO80 




Together, these data validate that INO80-C has two distinct targeting classes 
genome-wide: one class that contains a Canonical INO80-C that facilitates gene 
activation by establishing or maintaining open chromatin at regulatory elements that 
correlate with active transcription, and a second class that lacks representative subunits 
from each of its structural modules, associates with repressive chromatin features and 
gene repression, and is dispensable for maintaining inaccessible chromatin. Additional 
evidence suggests that activation of NC-INO80 sites may require coordination from 
multiple cooperative proteins and complexes.  
We next sought to investigate whether perturbation of heterochromatin would be 
sufficient to activate NC-INO80 targets. We hypothesized that PRC2 and H3K27me3 
created a local chromatin environment impermissible to INO80-C assembly and 
remodeling function. Therefore we perturbed the epigenome using a potent EZH2 
methyltransferase inhibitor EPZ-6438 (Knutson et al. 2013, 2014) to determine if 
inhibition EZH2 activity would permit activation of NC-INO80 targets and if so, the 
process was INO80-C dependent. We titrated the drug in HepG2 cells (Fig. 4.10A) and 
observed potent inhibition of H3K27me3 globally by western blot (Fig. 4.10A), while 
levels of EZH2 were not perturbed, as expected (Fig. 4.10A). We compared EPZ-6438 
to a different EZH2 inhibitor (GSK126) but observed less effective inhibition so we 
proceeded with EPZ-6438 (Fig. 4.10B). We utilized 1.0uM EPZ-6438 to maximize 
H3K27me3 reduction and minimize toxicity. Notably, we observed a marked increase in 
H3K27ac levels following 120 hours of drug treatment (Fig. 4.10A,C) consistent with 
other chemicals that perturb H3K27me3 (Xu et al. 2015) and antagonism between 
H3K27me3 and H3K27ac (Tie et al. 2009; Pasini et al. 2010). Additionally, the increase 
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in H3K27ac was attenuated when we introduced siRNA to either MCRS1 or INO80 in 
the presence of drug treatment (Fig. 4.10C,D). These data implicate INO80-C in 




Figure 4.10. INO80-C Facilitates H3K27ac Following EZH2 Inhibition. A. Western 
blots on whole cell lysates and acid extracted histones following 120 hour treatment with 
DMSO or EPZ-6438. B. Western blots on acid extracted histones following 120 hour 
treatment with DMSO or GSK126.C. Treatment of HepG2 cells with DMSO or 1.0 μM 
EPZ-6438 for 120 hours followed by western blotting for histone modifications. 
Additionally, cells were treated with negative control siRNAs or targeting INO80 or its 
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accessory subunit MCRS1. Western blotting was carried out using fluorescent reagents 
and quantitated relative to H3 as a loading control. D. Quantitation of experiments 
depicted in B. Mean and standard deviation for 3 independent experiments are plotted.  
 
 Motivated by the large increase in global H3K27ac following treatment with EPZ-
6438 and its dependency on INO80-C (Fig. 4.10A,C), we sought to directly test how 
localization of H3K27ac was altered by EZH2 inhibition. We performed quantitative 
ChIP-seq for H3K27ac in cells treated with DMSO or EPZ-6438 (Orlando et al. 2014). 
Inclusion of reference chromatin from Drosophila melanogaster allows the accurate 
interpretation of ChIP-seq signal given the global increase in H3K27ac (Orlando et al. 
2014; Egan et al. 2016). We compared H3K27ac signal in the two conditions at 
Canonical and NC-INO80 targets. Consistent with the global upregulation of H3K27ac 
we saw moderate increases in both classes broadly distributed across all sites (Fig. 
4.11B,D). Likewise, we observed a marked increase in H3K27ac abundance at 
individual NC-INO80 loci (Fig. 4.11C). The level of signal at NC-INO80 targets following 
treatment with EPZ-6438 was lower than the level of signal found at Canonical INO80 
sites in DMSO-treated cells, likely reflecting that not all cells in the population gained the 
modification. Together, these data support an EZH2-mediated repression of NC-INO80 
targets and a cooperative activation of NC-INO80 sites between INO80-C and P300 
when EZH2 activity is diminished. Moreover, accumulation of H3K27ac and the 
dependence of this activation on INO80-C (Fig. 4.10C,D) are consistent with a model 
that relieving the activity of EZH2 at these sites may stimulate the assembly of 
remaining INO80-C subunits at these targets. Finally, the global increase in H3K27ac 
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was localized to both Canonical and NC-INO80 sites, consistent with a global activating 
role for INO80-C, likely in conjunction with the P300 and other cooperative machinery. 
 
 
Figure 4.11. Inhibition of EZH2 Activity Leads to Increase in H3K27ac at Canonical 
INO80 and NC-INO80 Targets.  A. Western blot analysis indicating the potent effect of 
treating HepG2 cells with EPZ-6438. B. H3K27ac signal from quantitative ChIP-seq 
experiments aligned at the midpoint of Canonical INO80 or NC-INO80 (+/- 5kb). C. 
Representative NC-INO80 targets that acquire H3K27ac following EPZ-6438 treatment. 
D. Quantification of signal over peaks in A. Asterisks denotes p.value < 2.2e-16 by 
Wilcoxon test. Due to large number of points, outliers were not plotted, box and 
whiskers represent 50% of the data within the box, and whiskers extend to 1.5 the 
interquartile range.  
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Additionally, the increase in H3K27ac was apparent at multiple chromHMM 
states, where treatment with the inhibitor led to a broad upregulation of H3K27ac signal 
supporting the observed global increase in H3K27ac (Fig. 4.11A). In particular, sites 
predicted to be Weak Enhancers, Weak Promoters, and Repressed loci exhibited 
increases in H3K27ac (Fig. 4.12). These data support the observation NC-INO80 
targets accumulate H3K27ac following EZH2 inhibition.  
 
Figure 4.12. H3K27ac Signal at ChromHMM States following EZH2 Inhibition. A. 
H3K27ac signal was measured in HepG2 cells treated with DMSO or EPZ-6438 for 120 
hours. Signal is aligned over chromHMM features (Ernst et al. 2011) and each feature is 
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scaled to 1kb, with +/- 5kb of flanking region taken. We analyzed only those classes of 
chromHMM that were prevalent in INO80-bound regions. Bolded chromHMM features 
serve to draw the reader’s attention based on the text.  
Next, we performed ChIP-seq for MCRS1 and YY1 in DMSO and EPZ-6438 
treated HepG2 cells to determine if INO80-C subunits were redistributed across the 
genome following inhibition of EZH2 and the generation of new H3K27ac patterns (Fig. 
4.11, 4.12). Interestingly, we observed only minor increases in occupancy by MCRS1 
and YY1 across the genome (Fig. 4.13), as well as increased signal for MCRS1 and 
YY1 at NC-INO80 targets than previous experiments demonstrated (Fig. 3.1, Fig. 4.4, 
Fig. 4.7). The subtle increase in signal between DMSO and EPZ-6438 conditions is 
consistent with an accumulation of signal following H3K27me3 depletion, however the 
lack of robust redistribution of MCRS1 and YY1 suggests that inhibition of EZH2 
catalytic activity alone is unable to sufficiently perturb the epigenome to the extent 
necessary to reorganize chromatin binding patterns by INO80-C and other chromatin 
regulators completely when measured by ChIP-seq. We attempted to generate cell lines 
that lacked EZH2 protein in order to test if loss of EZH2 binding would be sufficient to 
redistributed INO80-C localization, however we were unable to generate stable cell lines 
engineered to lack EZH2 protein perhaps because EZH2 protein levels are important for 
cell viability in these cells.  
The discrepancy in occupancy that we observed at NC-INO80 sites contrasts our 
prior experiments and our analysis of publicly available data. One explanation is that 
these ChIP-seq experiments were particularly robust. If so, it is likely that these subunits 
bind a proportion of NC-INO80 targets in the population of cells treated with DMSO and 
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EPZ-6439 used for these ChIP-seq datasets that previous experiments in untreated 
cells did not detect. Inclusion of an INO80 ChIP-seq in these treatments (DMSO, EPZ-
6438) would have enabled us to derive new NC-INO80 targets in control versus 
experimental conditions.  
Regardless, we were encouraged that the signal for the MCRS1 and YY1 at 
Canonical INO80 and NC-INO80 targets in these treatments were markedly different 
suggesting our categorization of INO80-C targeting still discriminated two classes of 
INO80-C targeting, despite elevated signal we observe at NC-INO80 sites in these 
conditions. At Canonical INO80 targets, signal for MCRS1 and YY1 were nearly double 
the signal at NC-INO80 targets (Fig. 4.13). Therefore despite the unexpected 
observation that HepG2 cells treated with DMSO and EPZ-6438 yielded higher signal 
for MCRS1 and YY1 at NC-INO80 sites than we anticipated, we remained encouraged 
by the contrasting levels of INO80-C subunit enrichment and epigenomic features 
therein. For the remaining experiments we elected to study the effect of INO80-C in 
activating NC-INO80 targets when HepG2 cells were perturbed with EZH2 chemical 





Figure 4.13. MCRS1 and YY1 ChIP-seq in HepG2 Treated with EPZ-6438.  
A. ChIP-seq signal from quantitative ChIP-seq experiments aligned at the midpoint of 
Canonical INO80 or NC-INO80 (+/- 5kb). Rows in heatmaps are genes in HepG2 cells 




To determine if EZH2 inhibition potentiated de-repression of genes near NC-
INO80 targets, we performed RNA-seq in HepG2 treated with DMSO or EPZ-6438 (Fig. 
4.14A). Following treatment with EPZ-6438, we observed 461 genes increased and 288 
genes decreased at an FDR of 0.05 (Fi.g 4.14A). Strikingly, when we reduced the levels 
of INO80-C subunit MCRS1 in the presence of EPZ-6438, the de-repression was 
mitigated and only 120 genes were up-regulated (Fig. 4.14B). Moreover this effect was 
especially pronounced at NC-INO80 targets (Fig. 4.14C). We did not observe the same 
level of de-repression at the Canonical INO80 targets, likely due to the fact that the 
genes near Canonical INO80 targets were already expressed at higher levels (Fig. 3.4, 
Fig. 4.4B, Fig. 4.5C).  
 
Figure 4.14. De-repression of NC-INO80 Targets Depends on INO80-C Subunit 
MCRS1. A,B. Expression changes following treatment with EPZ-6438 and control 
siRNA or siMCRS1 by RNAseq. Red points indicate FDR < 0.05. B. Log2 fold changes 
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of genes assigned uniquely to either Canonical INO80 or NC-INO80 sites following 
treatment with EPZ-6438 and a control siRNA or an siRNA targeting MCRS1. Asterisk 
denotes Wilcoxon p-value < 0.01.  
 
 Given that MCRS1 participates in non-INO80 complexes (Mendjan et al. 2006; 
Cai et al. 2010; Raja et al. 2010; Chelmicki et al. 2014), we verified that NC-INO80 
target gene de-repression was dependent on INO80-C by performing RT-qPCR. We 
tested six genes that exhibited de-repression following EPZ-6438 treatment that was 
dependent on MCRS1 according to our RNA-seq (Fig. 4.14). Of the six genes, four 
exhibited a de-repression that was dependent on the INO80 protein, although two were 
statistically significant. Additionally, a set of genes appeared to be de-repressed by 
EPZ-6438 in an INO80-independent fashion (Fig. 4.15). These data suggest that while 
the majority of NC-INO80 target gene de-repression we detect following EPZ-6438 are 





Figure 4.15. Validation of INO80-C Dependent Gene Expression Changes. A. 
Expression changes following treatment with EPZ-6438 and control siRNA or siINO80 
by qRT-PCR. Genes tested were dependent on INO80-C subunit MCRS1 following 
treatment with EPZ-6438. Error bars represent standard error. Asterisk indicates p value 
< 0.05.  
 
We also observed de-repression of NC-INO80 target genes following shRNA 
knockdown of EZH2 (Fig. 4.16). These data are consistent with the changes we 
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observe when inhibiting EZH2 methyltransferase activity using EPZ-6438.
 
4.16. Loss of EZH2 Protein De-represses NC-INO80 Target Genes. A. Western blots 
on whole cell lysates following lentiviral transduction of HepG2 with either negative 
control shRNA or shRNA to EZH2 (Kim et al. 2015). B. Western blots on acid extracted 
histones following lentiviral transduction. C. Quantitative PCR on RNA isolated from 
HepG2 following lentiviral transduction. Log2 fold change is plotted for two shRNA to 
EZH2, relative to negative shRNA and normalized to the geometric mean of GAPDH, 
HPRT, and TBP. N=4, individual points are plotted and error bars represent standard 
error of the mean. 
 
Finally, we performed RNA-seq in untreated HepG2 following knockdown of 
INO80 to determine the general contribution of INO80-C to gene expression. 
Interestingly, we observed global changes in gene expression following INO80 
knockdown, but we did not observe a preference for gene activation or repression (Fig. 
4.17). Fig. 4.17B demonstrates that genes near Canonical INO80 and NC-INO80 sites 
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did not skew toward high or low levels of expression following knockdown of INO80. 
These data contrast results indicating INO80 is a component of the suppressive MINC 
complex in yeast and mouse ES cells (Xue et al. 2017). Additionally, these data suggest 
that INO80-C may generally serve as a secondary contributor to gene expression, 
whereas its primary role is likely in remodeling nucleosomes so transcriptional activators 
and repressors can access the underlying DNA (e.g. MEF2 and P300).  
Finally, these results emphasize that NC-INO80 and MINC likely represent 
separate classes of INO80-C function (Xue et al. 2017; Runge et al. 2018). Our 
evidence suggests NC-INO80 serves as a incomplete, remodeling incapable class of 
targets by the INO80 ATPase, whereas MINC appears to be a specialized version of 
INO80-C that prevents aberrant transcription.  
 
 
Figure 4.17. Depletion of INO80 Protein Induces Global Bidirectional Gene 
Expression Changes. A. Expression changes following treatment with siINO80 #1 or 
siINO80 #2 by RNAseq. Western blot confirming efficient knockdown are represented 
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above in Fig. 4.8A. Red points indicate FDR < 0.05. 2448 genes increase in expression, 
while 2337 genes decrease. B. Log2 Fold Changes relative to non-targeting following 





To validate our observation that separate chromatin features correlate with 
distinct the compositions of INO80-C at genomic targets (Chapter 3), we mapped the 
INO80 ATPase and representative proteins from each of the three INO80-C modules in 
A549 lung cancer cells and human liver cancer cell line Huh7 using ChIP-seq. Our data 
confirmed that remarkably distinct classes of INO80-C targeting exist on chromatin in 
cells. Consistent with our prior work, the predominant class contained a histone 
modification signature consistent with active chromatin states (chromatin accessibility, 
H3K27ac, high levels of gene expression) and was occupied by all INO80-C subunits 
we mapped. The second class was marked by repressive chromatin features, such as 
chromatin inaccessibility, H3K27me3, and gene repression. Surprisingly, the second 
class, previously termed NC-INO80, contained an incomplete INO80-C that contained 
only the catalytic ATPase, INO80. We compared the targeting of INO80-C in Huh7 to 
our original discovery cell line HepG2, and found the location INO80-C sites were 
dynamic. Additionally, where changes in INO80-C targeting yielded cell-type specific 
Canonical INO80 or NC-INO80 sites, changes to chromatin structure and gene 
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expression varied between cell lines in a manner consistent with our predictions based 
on INO80-C targeting.  
We tested the mechanistic contribution of INO80-C to chromatin state and gene 
expression at its targets. We evaluated the features underlying Canonical INO80 and 
NC-INO80 targets and identified separate DNA motifs and gene ontology associations 
that correlated with expected features of the loci. We depleted cells of the INO80 
ATPase and determined that Canonical INO80 targets depended on INO80 for high 
levels of chromatin accessibility, whereas NC-INO80 targets were insensitive to the 
perturbation. These data suggest NC-INO80 targets may harbor a remodeling-
incompetent version of INO80-C.  
We inhibited EZH2 methyltransferase activity and observed a global 
accumulation of H3K27ac that was dependent on INO80-C. Notably, ChIP-seq in cells 
treated with EZH2 inhibitor EPZ-6438 revealed that H3K7ac accumulated at promoters 
of NC-INO80 targets, as well as other loci, and correlated with the de-repression of NC-
INO80 target genes. H3K27ac increased at regulatory elements genome-wide, in 
agreement with our global histone modification western blot data and other instances of 
genetic and chemical perturbations of PRC2 (Tie et al. 2009; Pasini et al. 2010; Knutson 
et al. 2014; Lee et al. 2014b; Xu et al. 2015; Zhang et al. 2016; Piunti et al. 2017). 
Critically, the de-repression of NC-INO80 targets and global H3K27ac upregulation was 
dependent on the INO80 ATPase and a mammalian-specific subunit of the human 
INO80 Complex, MCRS1. This subunit is not bound at NC-INO80 sites prior to 
H3K27me3 inhibition, suggesting that activation of these sites may require formation of 
Canonical INO80. Although we were unable to verify this hypothesis experimentally 
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using ChIP-seq, our application of analogous approaches to investigate the contribution 
of INO80-C to chromatin accessibility and gene regulation, and recent results from other 
groups (Yao et al. 2016; Zhou et al. 2017; Xue et al. 2017) point toward a 
heterogeneous model for INO80-C targeting and function genome-wide consistent with 
our findings.  
Additionally, the strong connection between INO80-C and H3K27ac suggests 
that P300 may function coordinately with INO80-C to facilitate chromatin accessibility 
and gene expression. In particular, INO80-C may be a secondary contributor to gene 
expression as its perturbation yielded bidirectional changes in gene expression. These 
results contrast the identification of the suppressive formation of INO80-C termed MINC 
that prohibits pervasive gene expression at chromatin targets bearing active and 
inactive features (Xue et al. 2017). In summary, our data indicate that the molecular 
composition of the human INO80-C is far more dynamic than previously anticipated and 
implicates PRC2 as antagonistic to INO80-C on a global and locus-specific scale.  
 
Local Assembly and Function of INO80-C 
Our discovery that NC-INO80 correlates with inaccessible chromatin suggests 
that the ATPase, when independent from its accessory proteins in vivo, is not able to 
facilitate chromatin accessibility. This is consistent with in vitro data for INO80-C activity 
(Jónsson et al. 2004; Chen et al. 2011, 2013; Watanabe et al. 2015; Yao et al. 2016; 
Zhou et al. 2017). Substantiating the idea that NC-INO80 is insufficient to remodel 
chromatin, ATAC-seq following knockdown of INO80 indicated that loss of INO80 
ATPase had no effect on heterochromatin at NC-INO80 targets. Surprisingly, Module 3 
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of the INO80-C does not contribute to INO80-C-dependent remodeling activities in vitro 
(Chen et al. 2011, 2013), but Module 3 protein MCRS1 appears to be required for gene 
activation at NC-INO80 targets following H3K27me3 inhibition (Fig. 5). Although we did 
not map all 15 INO80-C subunits, our results are consistent with biochemical studies in 
that any subunits (Module 1, 2 or 3) involved in INO80-C function are likely absent from 
the NC-INO80 subset given the robust heterochromatin signature and gene repression 
at the class. Likewise, that de-repression of NC-INO80 sites is dependent on MCRS1 by 
RNA-seq indicates that INO80-C may re-localize to NC-INO80 targets to facilitate gene 
activation following perturbation of the genome with EPZ-6438, which presumably 
includes other INO80-C subunits.  
Western blots on histone extractions demonstrated that global levels of H3K27ac 
were dependent on MCRS1 and INO80 in the context of H3K27me3 inhibition 
suggesting that the interplay between INO80-C and PRC2 is critical at a level beyond 
the subset of INO80 ATPase targets that lack INO80-C subunits. H3K27me3 does not 
exist in yeast and MCRS1 is a mammalian-specific component of INO80-C. Therefore 
crosstalk between INO80-C and PRC2 in this manner may be restricted to mammals or 
other metazoans bearing these forms of repressive chromatin.  
How might EZH2 activity influence INO80-C targeting? One possibility is that the 
H3K27me3 modification interferes with the recruitment of INO80-C accessory subunits. 
If so, then the generation of de novo H3K27me3-depleted histones following EZH2 
inhibition are suitable for INO80-C targeting, yielding INO80-C remodeling activity and 
P300 to activate gene expression. Cell-type specific transcription factors, such as the 
NC-INO80 enriched MEF2 family proteins, may also play a role in activating NC-INO80 
 101 
targets is specific contexts. Alternatively, INO80-C accessory subunits may be recruited 
by or in conjunction with P300. P300 and H3K27ac are known to be antagonized by 
H3K27me3 from PRC2 (Tie et al. 2009; Pasini et al. 2010). Under this scenario, P300 
may first target and acetylate demethylated H3K27 residues, initiate recruitment of the 
INO80-C. INO80-C may also reinforce this state through its remodeling activity, leading 
to stable H3K27ac at these loci. Additional studies on INO80-C should be carried out in 
order to clarify the many features that may contribute to INO80-C assembly and 
heterogeneity in relation to PRC2 and other chromatin modifiers.  
Given the multitude of histone modifications, post-translational modifications to 
proteins, non-coding RNA molecules, and chaperone proteins that facilitate protein 
complex assemblies, it is possible that other epigenetic regulators play a role in 
regulating the interaction between INO80-C and PRC2. One possibility is that specific 
post-translational modifications on INO80-C itself affect its ability to stably form a 
complex. For example, there is biochemical evidence that the INO80 ATPase can be 
modified by post-translational modifications (Lee et al. 2014a). Numerous histone 
modifying proteins, including P300, are capable of post-translationally modifying non-
histone substrates (Glozak et al. 2005). One promising candidate for a post-translational 
modification to INO80-C would be acetylation, given its interaction with P300 (Chapter 
3) and evidence that P300 acetylates other proteins, including itself, to promote 
H3K27ac deposition (Gu and Roeder 1997; Thompson et al. 2004; Li et al. 2007; Tang 
et al. 2008). Additionally, our inability to detect MCRS1 and YY1 relocalization to NC-
INO80 targets following DMSO and EPZ-6438 treated HepG2 cells by ChIP-seq, in 
contrast to genetic evidence that MCRS1 is required for the activation of gene 
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expression of NC-INO80 targets in the same contexts by RNA-seq, suggests that RNA-
seq may be more sensitive than ChIP-seq for detecting these changes and that 
additional chromatin signals may be required to alter the chromatin landscape 
sufficiently to detect robust changes in localization of INO80-C subunits. Because 
chromatin is subject to multivalent regulation and conformational arrangements, 
identifying the array of signals that contribute to INO80 targeting will further clarify the 
features that drive INO80-C to specific sites.  
Mechanistically, there are many exciting questions that emerged from these 
studies regarding INO80-C targeting and function. Future genetic studies may help 
determine which INO80-C subunits, or other chromatin regulators, are required to 
activate NC-INO80 sites. Perhaps certain INO80-C subunits, such as a core remodeling 
complex, are required for activation of these repressed targets, while others are 
dispensable. Biochemical evidence suggests INO80-C possesses a core set of subunits 
that is able to modulate nucleosome position (Willhoft et al. 2016). Additionally, is there 
a sequence to INO80-C assembly at its targets? Evidence supports a model for 
stepwise INO80-C assembly (Zhou et al. 2017), yet questions regarding many details of 
the assembly remain unanswered. For instance, are sets of INO80-C subunits or 
modules recruited to the complex simultaneously and are they facilitated by co-





Implications of PRC2-INO80 Dynamics in Development and Disease 
We envision that the PRC2-INO80 dynamics may be particularly critical in cell 
lineage commitment. Polycomb establishes gene repression programs that enable cell-
type specific gene regulation (Simon and Kingston 2013), yet how these programs are 
initiated and maintained remains elusive. Determining if PRC2-INO80 antagonism 
facilitates these cell-type specific programs may provide insight into the biological 
importance of the INO80-C heterogeneity. Numerous reports indicate that PRC2 and 
H2A.Z occupy bivalent sites in ES cells that resolve throughout development 
(Creyghton et al. 2008; Ku et al. 2012; de Dieuleveult et al. 2016), implicating that 
INO80-C functionality through its role in H2A/H2A.Z exchange (Watanabe and Peterson 
2010) could be influenced by PRC2 targeting. Segala et al showed that INO80-C 
responds to de-ubiquitinated H2B in order to exchange H2A-H2B dimers for H2A.Z/H2B 
at enhancers (Segala et al. 2016). Perhaps INO80-C utilizes a combinatorial readout of 
post-translational modifications, including PRC2-mediated H3K27me3, to recognize 
competent target loci prior to assembling its molecular partners for remodeling of 
nucleosomes. Clarifying the multivalent chromatin features that influence INO80-C 
targeting and activity will be an important topic in future research.  
 
Materials and Methods:  
Cell Culture 
HepG2 and Huh7 cells were purchased from the ATCC and grown in DMEM 
(Gibco, Life Technologies) supplemented with 10% Fetal Bovine Serum and 
penicillin/streptomycin (100 units/mL). 293T cells were purchased from the ATCC and 
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grown in DMEM (Gibco, Life Technologies) supplemented with 10% Fetal Bovine 
Serum, penicillin/streptomycin (100 units/mL) and glutamine.  
  
ATAC 
ATAC was performed as previously described (Buenrostro et al. 2013), with 
minor modifications. Cells were frozen in 10% DMSO in complete media until all groups 
were ready. 50,000 cells were used in each transposition reaction. We used a lysis 
buffer containing 0.05% Ipegal, rather than the original protocol’s 0.1% Igepal ca-630. 
 
Antibodies 
Antibodies used include the following: β-Actin: Cell Signaling 4970 (Western). β-
Tubulin: Sigma T8328 (Western). EZH2: Millipore 07-400 (Western). FLAG: Cell 
Signaling 2368 (Western). HA: Sigma H3663 (IP, Western). H3: Kindly provided by 
Laboratory of Brian Strahl. H3K27ac: Active Motif 39133 (ChIP, Western). H3K27me3: 
Millipore 07-449 (Western), Abcam ab6002 (Western). INO80: Abcam ab105451 (ChIP, 
Western). MCRS1: Proteintech 11362-1-AP (ChIP, Western). RUVBL1: Bethyl A304-
716A (ChIP) and Abcam ab51500 (Western). RUVBL2: Bethyl A302-537A (ChIP) and 
Abcam ab89942 (Western). YY1: Santa Cruz sc-1703 (ChIP, Western). 
  
siRNA Knockdown 
HepG2 were cultured as above, then reverse transfected in the absence of 
antibiotics with 50nM silencer select siRNA and 5μL RNAiMAX per condition (NTG, 
siINO80 #1, and siINO80 #2). 2E6 cells were plated per condition. We performed each 
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experiment in biological triplicate and performed technical triplicates in order to measure 
RNA, protein, and nucleosome occupancy changes by RNA-seq, Western Blot, and 
ATAC-seq. Specifically, 50nM siRNA and 5μL RNAiMAX were diluted into 0.5mL 
Optimem (Life Technologies) and incubated for 20 minutes at room temperature. 
Mixtures were plated with 2E6 cells per condition, rocked gently, and incubated for 72 
hours before harvest. The following siRNAs were obtained from Life Technologies: 
Silencer select negative control AM4611 (siNTG), Silencer select s224308 (siINO80 
#1), Silencer select 29255 (siINO80 #2), and Silencer select s20435 (siMCRS1).  
 
shRNA Knockdown Experiments 
shRNA construct targeting INO80 (TRCN0000107555), EZH2 (shRNA-1: 
TRCN00000040073; shRNA-2: TRCN00000040076), and a non-silencing construct 
were used to generate lentivirus by transfecting HEK293T cells with the pLKO.1 
lentiviral constructs, pMD2.G and psPAX2. psPAX2 and pMD2.6 were a gift from Didier 
Trono—Addgene plasmid # 12260 and plasmid # 12259). After 72 hours viral 
supernatant was harvested concentrated using Lenti-X (Clontech). For knockdown 
experiments, cells were treated with lentivirus for 2 days, then selected with puromycin 
for 2 days.  
 
Drug Treatment and siRNA Knockdown 
Cells were treated with either 0.1% DMSO or 0.5-10μM EPZ-6438 
(MedChemExpress, HY-13803) in DMEM (with 10% FBS, 1% antibiotics as above). 
Medium was replaced daily. When performing simultaneous siRNA knockdown, cells 
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were treated with 0.1% DMSO or 1.0μM EPZ-6438 for 3 days, then subjected to reverse 
transfection (as above) in the presence of DMSO or EPZ-6438 without antibiotics. 
Following 48 hours of transfection the cells received an additional 2mLs of fresh DMSO 
or EPZ-6438-containing DMEM for 24 hours, then harvested.  
 
Over-expression and Immunoprecipitation 
Transfection and Lysate Preparation 
293T cells were cultured as above, then transfected with FLAG-INO80 and HA-
EZH2.  FLAG-INO80 (Addgene #44149) was a gift from Joan Conaway (Chen et al. 
2011).  HA-EZH2 (Addgene #24230) was a gift from Kristian Helin (Bracken et al. 
2003). For transfection, 28μg of DNA was transfected per 10cm dish. Plates received 
either 28μg of pCMV10 (control), 14μg pCMV10 + 14μg FLAG-INO80, 14μg pCMV10 + 
14μg HA-EZH2, or 14μg FLAG-INO80 + 14μg HA-EZH2. Cells were transfected by 
preparing 50μL polyethylamine in 1.5mL Optimem per plate. Plasmids were diluted 
separately in 1.5mL Optimem. Preparations were mixed 1:1 and incubated at room 
temperature for 20 minutes. 7mLs of fresh media (no antibiotics) was added to cells, 
then 3mLs of the appropriate DNA mixture. Cells were harvested after 48 hours. Plates 
were washed in 5mLs PBS at room temperature. Then 500μL of Lysis Buffer (50mM 
Tris-Cl pH 7.4, 150mM NaCl, 1mM EDTA, 1% Triton X100) were added to plates and 
scraped into 1.5mL centrifuge tubes. Tubes were rotated for 30 min at 4°C then 
centrifuged for 10 minutes at full speed. Supernatants were transferred to fresh tubes. 




Prior to beginning the IP, we washed Dynal Protein G beads 3 times with PBS + 
0.5% BSA at 4°C. We resuspended beads in 400μL of 1X PBS + 0.5% BSA, then 
added 1μL of HA antibody and incubated overnight at 4°C. The following day, we 
washed beads 2X with 400μL 1X PBS + 0.5% BSA, then 2X with Lysis Buffer. Lysates 
(500μg/IP) were added to antibody-conjugated beads and incubated overnight. 50μg of 
lysate was utilized for IP input. Beads were washed 3 times with Lysis Buffer, then 
samples were eluted in 40μL 1X Laemmli Buffer + DTT and boiled for 5 minutes.  
 
FLAG Immunoprecipitation 
We warmed Anti-FLAG M1 Agarose Affinity Gel (Sigma) at room temperature for 
30 minutes. The slurry was resuspended by pipetting. Slurry (50μL/condition) was 
prepared by centrifugation and washing; resin was centrifuged at 8000 RPM for 30 
seconds and supernatant was removed. Resin was washed with 500μL TBS and 
rotated for 1 minute, then centrifuged and washed again. After the second wash, the 
resin was prepared with 500μL 0.1M glycine Ph 3.5 for 1 minute, centrifuged for at 8000 
RPM for 30 seconds, and supernatant was removed immediately. Resin was washed 
with 500μL as above twice more, then twice with Lysis Buffer. Lysates (500μg/IP) was 
raised to 1mL volume, then 50μL resin was added and incubated overnight. 50μg of 
lysate was utilized for IP input. IPs were washed 3 times with 0.5mL Lysis Buffer and 






Huh7 cells were fixed using 0.3% formaldehyde in 1X PBS for 30 minutes at 4°C. 
Fixative was quenched with 1/10 volume of 2M glycine for 5 minutes at room 
temperature. Cells were pelleted at 2000 rpm for 10 minutes at 4°C, then washed 3 
times by resuspension in 50mLs of ice cold 1X PBS and centrifugation at 2000 rpm for 




ChIP was performed as previously described (Raab et al. 2015). Briefly, prior to 
beginning the ChIP, we washed Dynal Protein A beads 3 times with PBS + 0.5% BSA at 
4°C. We resuspended beads in 400μL of 1X + 0.5% BSA, then added 4-10μg of 
antibody and incubated overnight at 4°C. The following day, we thawed the fixed cells 
for 30 minutes on ice. We then resuspended each pellet in 1mL swelling buffer (25mM 
HEPES + 1.5mM MgCl2 + 10mM KCl + 0.1% Igepal). We added 10mM PMSF and 
Proteinase Inhibitor Cocktail, and pooled the samples. The pooled samples were 
inverted for 10 minutes at 4°C then dounced 20 strokes. We pelleted nuclei at 2000 rpm 
for 7 minutes at 4°C. Nuclei were resuspnded in 5mL Sucrose Buffer A (0.32M Sucrose, 
15mM Hepes pH 7.9, 60mM KCl, 2mM EDTA, 0.5mM EGTA) + PMSF and Proteinase 
Inhibitor Cocktail. Then 5mL Sucrose Buffer B (30% Sucrose, 15mM Hepes pH 7.9, 
2mM EDTA, 0.5mM EGTA) was gently added. We centrifuged the sucrose solution at 
3000 rpm for 10 minutes at 4°C, then washed the pelleted in 10mL MNase Digestion 
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Buffer (15mM Hepes pH 7.9, 60mM KCl, 15mM NaCl, 0.32M Sucrose) at 2000 rpm for 
7 minutes at 4°C. The pellet was resuspended in 1mL MNase Digestion Buffer per 4e7 
cells + 3.3μL 1M CaCl2 per mL + PMSF and Proteinase Inhibitor Cocktail, then 
incubated for 5 minutes at 37°C to warm. We added MNase at 0.5μL/1e7 cells and 
incubated for 15 minutes at 37°C. Following digestion, the MNase was chelated using 
1/10 volume 0.5M EDTA on ice for 5 minutes. We added 1 volume of 2X IP Buffer 
(20mM TrisCl pH 8, 200mM NaCl, 1mM EDTA, 0.5mM EGTA), then passed the sample 
for a 20G needle 5 times and a 25G needle 5 times. The sample was split into 
microcentrifuge tubes and centrifuged at 13,000 rpm for 15 minutes at 4°C to remove 
debri. We pooled the supernatants and placed on ice for 1 hour. The pellets were 
resuspended in 1mL 1X IP Buffer (10mM Tris-HCl pH 8, 100mM NaCl, 1mM EDTA, 
0.5mM EGTA) and inverted for 1 hour at 4°C. Then we centrifuged the sample and 
mixed the supernatant with S1. We added 1% Triton-X 100 to the chromatin. The 
sample was split evenly to the prepared beads, after they were washed twice with 1X 
PBS + 0.5% BSA and twice with 1X IP Buffer. We saved 10% of the sample for input 
and incubated the IPs overnight at 4°C. The following day we washed the beads 10 
times with Agilent RIPA wash by adding 1mL wash buffer and inverting for 4 minutes at 
4°C. Beads were subsequently washed one time with 1X TE + 50mM NaCl before 
elution at 65°C with agitation using 100μL 1% SDS + 100mM NaHCO3 made freshly. 
We removed the supernatant and treated with 5μL of 5M NaCl overnight to reverse the 
crosslinks. We cleared RNAs and proteins by adding 3μL RNaseA for 45 minutes at 
37°C and then Proteinase K for 2 hours at 56C. Precipitates were purified using the 
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Zymo Clean and Concentrator ChIP Kit and quantified using qubit before library 
preparation. 
 
Whole Cell Lysis 
Cells were washed with PBS, then lysed for 30 minutes with cold RIPA buffer 
(10mM Tris-Cl pH 8.0, 140mM NaCl, 0.1% SDS, 0.1% sodium deoxycholate, 1% Triton 
X-100, 1.0mM EDTA, 0.5mM EGTA, and protease inhibitors). Cells were centrifuged at 
16,000 rpm for 20 minutes at 4°C. Supernatant were diluted in 2X Laemmli Buffer with 
0.1M DTT, boiled for 5 minutes, then stored at -20°C.  
 
Cell Fractionation 
Proteinase inhibitors and PMSF were used throughout. Cells were centrifuged at 
1200 RPM in swing bucket rotor for 2 minutes. Cell pellet was washed in 200μL cold 
PBS, centrifuged at 1200 rpm for 2 minutes, twice. Pellet was resuspended in 200μL 
Buffer A (10mM Hepes pH 7.9, 10mM KCl 1.5mM MgCl2, 0.34 M Sucrose, 10% 
glycerol, 1mM DTT) + 0.1% Triton X100. Resuspended pellet was incubated for 8 
minutes on ice then centrifuged at 1300 G for 5 minutes at 4°C. The supernatant (S1) 
was decanted and placed into a fresh 1.5mL tube and centrifuged at 15K G for 5 
minutes at 4°C. Supernatant S1 was decanted into a fresh 1.5mL tube on ice (1μL 
universal nuclease added). The pellet was washed once with Buffer A, then centrifuged 
at 1700 G for 5 minutes. Nuclei were lysed in 100μL Buffer B (3mM EDTA, 0.2mM 
EGTA, 1mM DTT) for 30 minutes on ice. Lysed nuclei were then centrifuged at 1700 G 
for 5 minutes at 4°C. The supernatant (S2) was collected and placed into a fresh tube 
 111 
on ice (1μL universal nuclease added). The pellet was washed once with 200μL Buffer 
B and centrifuged at 1700 G for 5 minutes. The pellet was resuspended in 80μL PBS + 
1μL universal nuclease and incubated for 10 minutes on ice (S4). 20μL DTT and 100μL 
2X Laemli buffer were then added to S4. 200μL 2X Laemli + 40μL  DTT were added to 
S2 and 100μL 2X Laemli buffer + 20μL DTT were added to S3. All samples were boiled 
for 5 minutes and stored at -20°C prior to western blot analysis. 
 
Histone Extraction 
Cells were scraped into 200μL of Triton Extraction Buffer (5% Triton in 1X PBS), 
then centrifuged for 10 minutes at 8,000 RPM 4°C. Pellet was resuspended in 100μL 
Triton Extraction Buffer and subjected to centrifugation again for 10 minutes at 8,000 
RPM at 4°C. Histones were extracted using 0.2N HCl overnight, centrifuged for 15 
minutes at full speed, then neutralized with 1M Tris-Cl pH 8.0.  
 
RT-qPCR 
RT-qPCR was performed by reverse transcribing RNA using Protoscript II (NEB: 
M0368L) followed by quantitative PCR using Ssofast EvaGreen Supermix (Bio-Rad: 
172-5203) reagents per manufacturer’s instructions on a Bio-Rad CFX-96 machine. 
Primers sequences: EZH2-F: ATGGGAAAGTACACGGGGAT; EZH2-R: 
ATTGACCAAGGGCATTCACC; WNT5B-F GCGAGAGAAGAACTTTGCCA; WNT5B-R: 
CAGGCTACGTCTGCCATCTT; SCTR-F: TCCACTACATCGTCTTCGCC; SCTR-R: 
TCCCCATTGAGGAAGCAGTA; HTRA1-F: CTCCTTTGCAATCCCATCTG; HTRA1-R: 
CGTGAGTGACATCATTCGGA; CXCR4-F: TCCAAGCTGTCACACTCCAA; CXCR4-
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R:CTCACACCCTTGCTTGATGA; GAPDH-F: CTTTGTCAAGCTCATTTCCTGGTAT; 
GAPDH-R: GTGAGGGTCTCTCTCTTCCTCTTGT; HPRT-F: 
GTTTGTTGTAGGATATGCCCTTGAC; HPRT-R: 
CTCCAGATGTTTCCAAACTCAACTT; TBP-F: TTCGGAGAGTTCTGGGATTG; TBP-R: 
CTCATGATTACCGCAGCAAA. INO80-F: AGGAAACCAACCGAGTGAAAG; INO80-R: 
TCACCAGGTTCACACCCTCT; ETV1-F: TTTATTGCCTGGACTGGTCG; ETV1-R: 
TTTCTGAATGCCCCAACG; SLC6A2-F: GGGCTGTTGTGTTTTTCGTC; SLC6A2-R: 
TCAGGACCTGGAAGTCATCTG; ZBTB7C-F: TCTGGCTGCTATCCTGGAGT; 
ZBTB7C-R: TTCACGATGCACTGGATCTC; LAMA1-F: ATCAGCACTGCCAAAGTGGA; 
LAMA1-R: GCACCATTGTTGACATGGAA; TMC5-F: TCTTGGCCTTCAGGAGTTTG; 





Reads were aligned to hg19 using bowtie2 (Langmead and Salzberg 2012) using 
the --sensitive parameters, and duplicates were removed using samtools (Li et al. 
2009). For visualization bigwig tracks were generated using Deeptools (version 2.2.2) 
bamCoverage tool with a binsize of 10bp and extending fragments to the approximate 
nucleosome size of 150bp. Tracks can be visualized using IGV (Robinson et al. 2011) 





Peaks were called using Macs2 (version 2.1.0 (Zhang et al. 2008)) using the 
narrowpeak mode using the following parameters. Qval = 0.001 --keep-dup-all --shift 37 
--nomodel --extsize 147. Additionally, we filtered the peaks against the ENCODE 
blacklist regions and further recursively merged any peaks within 500bp of the nearest 
peak.  
 
Definition of NC-INO80 sites 
We defined NC-INO80 and Canonical INO80 sites using a simple overlap 
approach. We used the filtered and merged peak files generated above to define INO80 
bound regions that did not have any overlap with any of the other INO80-C subunit 
sites. When comparing genes associated with the two classes, we assigned genes to 
the nearest peak. Any gene that was the nearest peak for both an NC-INO80 and 
Canonical INO80 peak was removed from downstream analysis (ontology and 
expression of genes associated with NC-INO80 or Canonical INO80-C peaks). 
 
Comparison with ENCODE Data  
Raw fastq files for YY1 were downloaded from the ENCODE project and 
processed as with other INO80-C subunits. H3K27ac, H3K27me3, and EZH2 data bam 
alignment files were downloaded and used to generate bigwig files as above. Coverage 
at regions of interest were generated using Deeptools (version 2.2.4 (Ramírez et al. 
2016) with the computeMatrix function using a binsize of 10bp using the bigwig files 
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generated above. These were further processed using the heatmapper module of 
deeptools or using ggplot2 in R (version 3.2.2)    
 
Quantitative ChIP-seq 
Quantitative ChIP-seq was carried out using Drosophila Spike-in chromatin and 
H2av antibody (Active Motif). 50ng of Drosophila chromatin was added to each ChIP 
prior to incubation with antibody bead complexes overnight. Remainder of ChIP was 
carried out as described above. Following high-throughput sequencing reads were 
separately mapped to hg19 or dm3 using bowtie2 as above. Uniquely mapping, non-
duplicate drosophila reads were counted for each sample and used to derive a 
normalization factor as described by Orlando et al. as 1 over the number of uniquely 
mapping non-redundant drosophila reads in millions (Orlando et al. 2014). Deeptools 
bamCoverage was used to generate bigWig files as above using --
normalizeUsingRPKM and setting the --scaleFactors to those derived using the 
drosophila counts. These scaling factors were 0.64 and 0.61 for DMSO treated cells 
and 1.28 and 1.25 for EPZ-6438 treated cells. These final bigWig files were then used 




50bp paired-end reads were sequenced on Hiseq2500. Nextera adapter 
sequences were trimmed using trim_galaore and reads were aligned using bowtie2 with 
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the -X 2000 setting. We removed any reads mapping to the mitochondrial genome and 
filtered any reads with a mapping quality less than 20 using samtools.  
 
Peak Calling 
Peaks were called using Macs2 (version 2.1.0 (Zhang et al. 2008)) using the 
narrowpeak mode using default settings and --keep-dup-all. We filtered peaks using the 
ENCODE blacklist and generated a union peak set for further analysis.  
 
RNA-seq Analysis 
Expression analysis was carried out on single end 50bp (siINO80) or 75bp 
(DMSO/EPZ-6438) reads. Gene expression levels were quantitated using kallisto (Bray 
et al. 2016). These data were converted to counts and summarized per gene using 
tximport (Soneson et al. 2015) and differential expression was carried out using 
DESeq2 (Love et al. 2014) using an FDR of 0.05 and no explicit fold change cutoff.  
 
Data Availability 
All raw and processed data are deposited under GEO accession number 
GSE97413. Reviewer access to data are available at:  
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=kjobegwwjhyrvwl&acc=GSE9741
3. ChIP-seq data is deposited under series GSE97411. RNA-seq data is deposited 
under series GSE97412. ATAC-seq data is deposited under series GSE97410. 
Processed peak calls for ChIP and ATAC experiments can be found in Supplemental 
Tables 1 and 2. Raw count and processed siRNA INO80 data are located in 
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Supplemental Table 3 and 4. Raw count and processed EPZ-6438 RNA-seq and siRNA 
MCRS1 data are located in Supplemental Table 5 and 6.
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CHAPTER 5: CONCLUSIONS, FUTURE DIRECTIONS, FINAL REMARKS 
Summary of Findings 
 Proper epigenomic regulation requires the concerted functions of hundreds of 
chromatin regulating proteins such as readers, writers, erasers, and movers. Improper 
epigenomic regulation can result from perturbations to these proteins and others. By 
controlling access to DNA through chromatin, cells protect their genomes and require 
adherence to relationships between chromatin regulators that modulate chromatin 
structure and gene expression in a deliberate fashion. Movers, in particular, constitute a 
highly specialized class of epigenomic regulator that possesses the unique ability to 
generate access to genomic DNA by mobilizing nucleosomes. Other regulators 
modulate chromatin accessibility by modifying histones or DNA through mechanisms 
that relax or constrict nucleosome arrays. However, no other class of chromatin 
regulator can create regions of chromatin accessibility or inaccessibility with such 
potency as movers. The unique and influential roles of movers in chromatin regulation 
are likely the basis for their high rate of mutation in cancer cells (Kadoch et al. 2013).  
At least 20% of all human tumors harbor mutations in movers (Kadoch et al. 
2013). This statistic suggests that movers provide cancer cells with growth advantages 
in ways other chromatin regulators do not. Movers are the most commonly mutated 
class of chromatin regulator in cancer, and arguably one of the most commonly mutated 
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protein classes in in general. Some cancer subtypes are prone to mutations in movers 
in almost all known cases. For example, members of SWI/SNF are mutated 75% of 
ovarian clear cell carcinoma cases (Kadoch et al. 2013), of which a subset have been 
investigated for aberrant SWI/SNF-dependent disease mechanisms. Mutations to 
ARID1A subunit of SWI/SNF co-occurs in tumors with activating mutations to the 
oncogene PIK3CA (Chandler et al. 2015). Combination of mutant ARID1A and PIK3CA 
drives formation of tumors in mice that closely resemble human ovarian clear cell 
tumors both histologically and molecularly, and negatively correlates with prognosis 
(Chandler et al. 2015). These information indicate the importance of investigating the 
principles of how movers function and drive biological programs. Identifying the types of 
relationships they engage in with other chromatin regulators and cell signaling cascades 
will help clarify tumor-promoting pathways in detail. 
At the beginning of this dissertation, little was known regarding the function of the 
INO80-C mover in terms of regulatory function. Its biochemical roles had been 
rigorously investigated (Conaway and Conaway 2009), but there was little known about 
its role in regulating the epigenome on a global scale. Given the dearth of information 
regarding INO80-C, we proposed to characterize its genomic distribution and 
investigate potential mechanisms of crosstalk between other chromatin regulators. We 
leveraged genomics approaches, molecular biology, and biochemistry to evaluate the 
contributions of INO80-C to chromatin accessibility and gene expression at its targets. 
Our efforts and work by laboratories at other institutions has revealed that INO80-C is 
far more heterogeneous in cells than previous studies suggested. Additionally, INO80-C 
engages in important crosstalk between other regulators that guide its role in molecular 
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assembly of its remodeling components, its chromatin remodeling function, and gene 
activation. In short, in recent years the field has progressed to understand how INO80-C 
function is regulated at its target sites through local chromatin architecture and co-
regulatory partners. These exciting advancements are summarized below.  
 
Two Classes of INO80-C Targeting 
Using genomics approaches, we established the identification of two distinct 
classes of INO80-C targeting within the human genome. INO80-C binds to one set of 
chromatin targets that are enriched for active epigenomic features (e.g. H3K27ac, 
chromatin accessibility) and a second set of targets enriched for repressive epigenomic 
features (e.g. H3K27me3, chromatin inaccessibility). Notably, the second set of INO80-
C targets lack accessory subunits that are representative of the three subunit modules 
within the INO80-C. These sites are termed Canonical INO80-C targets and NC-INO80 
targets, respectively.Given the inability of INO80 to hydrolyze ATP and mobilize 
nucleosome arrays in vitro lacking these subunit modules (Chen et al. 2013), it is 
unlikely that INO80 is catalytically active at NC-INO80 targets. Likewise, the INO80 
protein is a scaffold for the subunit modules of INO80-C suggesting that INO80-C may 
serve as a docking site for its subunit partners at its chromatin targets. Potentially, 
incomplete INO80-C exist throughout the genome as a means to regulate INO80-C 
activity in vivo.  
 Additional evidence indicates that local chromatin architecture may influence the 
ability of INO80-C to assemble and engage in remodeling activities. Biochemical 
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experiments indicated that INO80-C interacts with the HAT P300, which acetylated 
H3K27. We were unable to detect interactions between INO80-C and the HMT EZH2 
using endogenous approaches, suggesting that our approaches lack the appropriate 
sensitivity to enrich for the NC-INO80 subset or that EZH2 and INO80 do not physically 
interact. Interestingly, we detected an interaction between INO80 and EZH2 when both 
are overexpressed in 293T cells, but detected no interaction when one was 
overexpressed alone (Fig. 4.2). It is possible that the artificial context of EZH2 and 
INO80 overexpression exceeds endogenous, biological relationships between the two 
proteins and that the detected interaction is not authentic. Regardless, we tested 
hypotheses and generated data that supports an oppositional relationship between 
INO80-C and PRC2. Moreover, our data support a model where INO80-C is likely a 
component of chromatin machinery than facilitates chromatin accessibility and H3K27ac 
leading to gene activation, in contrast to the repressive PRC2. Additionally, the robust 
physical interaction between INO80-C and P300 implicate the two proteins in a joint 
mechanism for facilitating activated chromatin states.  
Interestingly, work by Xue et al. indicated that in yeast and murine embryonic 
stem cells, the INO80 protein forms a complex with transcriptional modifiers MOT1 and 
NC2, termed MINC that suppresses transcription at genomic loci with both active and 
inactive chromatin features (Xue et al. 2017). MOT1 and NC2 were known to suppress 
transcription by inhibiting the function of transcriptional activator TBP (van Werven et al. 
2008; Koster et al. 2014). The implication of the INO80 protein in transcriptional 
repression, in view of our data that INO80-C is unlikely to drive specific gene regulatory 
programs, suggests that the INO80 ATPase could be a dynamic scaffold for INO80-C 
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related subcomplexes with discrete functions in epigenomic regulation. The outputs of 
INO80-C regulation may be variable depending on co-regulatory factors such as MOT1 
and NC2, P300, or EZH2 targeting.  
These data introduce a new paradigm in the INO80-C field. Because the 
SWI/SNF family of movers is heterogenous, the recent discoveries for INO80-C 
heterogeneity underscore the importance of mover composition and variability across 
families. Interestingly, some subunits are common among movers from different 
families, perhaps serving as a topic for future investigation into coordinative mover 
function across mover families (Chapter 3) (Runge et al. 2016). Additionally, our 
discovery that INO80-C interacts with P300 indicates that there is an interesting 
mechanism for target activation by P300 and INO80-C. The absence of a physical 
interaction between INO80-C and PRC2, and the relationship between MINC targets in 
murine cells and NC-INO80 targets in human cells, suggests that an important 
alternative INO80-C mechanism may exist to facilitate or maintain repressive chromatin 
in eukaryotes.  
 
Conservation of Two INO80-C Classes in Independent Cell Lines 
We extensively validated our discovery of heterogeneity for INO80-C in human 
cells. We analyzed publically available data in the lung cancer cell line A549 to 
determine if other groups have overlooked the existence of INO80-C heterogeneity. 
Indeed, our analyses revealed a class of NC-INO80 sites in A549 that shared features 
with NC-INO80 sites in HepG2. We performed our own additional ChIP-seq 
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experiments for INO80-C subunits in the liver cancer cell line Huh7. These data 
revealed, again, a class of NC-INO80 sites that lacked signal for other INO80-C 
subunits aside from the INO80 ATPase and harbored a heterochromatin and gene 
repression signature. Together, these data strongly support our initial findings from 
HepG2 cells. 
We used Huh7 cells as a surrogate for correlative comparisons between cell 
lines. We identified four groups of INO80-C localization changes that correlated with 
chromatin accessibility, gene expression, and most importantly, INO80-C subunit 
localization across cell lines. In other words, these data indicated that changes in 
INO80-C localization were predictive of changes to chromatin state and gene activity 
across cell lines. For example, an NC-INO80 site in HepG2 cells that is differentially 
targeted as a Canonical INO80 target in Huh7 cells, exhibited increased chromatin 
accessibility and expression of local genes in Huh7 cells. As stated elsewhere, these 
data implicate INO80-C as a component of the chromatin modifying machinery that 
facilitates chromatin accessibility and gene expression. Alternatively, similar to 
oppositional HAT and HDAC function at sites of open chromatin and gene activity 
(Wang et al. 2002a, 2009), these data don’t exclude the possibility that INO80-C is a 
component of chromatin machinery that prevents pervasive transcription by suppressing 
excessive chromatin accessibility at active regions, as reported described for MINC 
(Xue et al. 2017).  
We returned to HepG2 cells as an experimental model to refine our 
understanding of INO80-C contributions to chromatin regulation. We performed siRNA-
mediated knockdown experiments to deplete cells of the INO80 ATPase. Following 
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INO80 knockdown, NC-INO80 sites exhibited minimal changes in chromatin 
accessibility measured by ATAC-seq, consistent with the INO80 ATPase serving a 
dispensable role establishing or maintaining the local chromatin state. In contrast, 
Canonical INO80 targets exhibited a striking decrease in chromatin accessibility 
indicating that the INO80 ATPase, and presumably its scaffolding function for INO80-C, 
are required for the high levels in accessibility at these sites. These data suggest our 
categorization of Canonical INO80 and NC-INO80, and the observation of MINC in 
yeast and mouse ES cells, refer to separate functions for INO80-C.  
We next correlated the changes in accessibility with gene expression. While 
knockdown of INO80-C caused global gene expression changes in HepG2 cells, genes 
near both Canonical INO80 and NC-INO80 targets exhibited bidirectional changes in 
expression. Whereas an activating role for the INO80-C in chromatin accessibility 
suggested that INO80-C is involved in facilitating gene activation, the bidirectional 
changes in gene expression following knockdown of the INO80 ATPase suggests that 
INO80-C may not direct gene expression directly. Instead, targeting by INO80-C to a 
locus may facilitate increases chromatin accessibility, but the underlying gene 
expression of nearby loci is dependent on separate machinery. One explanation could 
be that INO80-C serves an indirect role in gene regulation but a direct role in mediating 
chromatin accessibility.  
 
Perturbation of EZH2 Yielded Activation of NC-INO80 Targets 
 We demonstrated that heterochromatin at NC-INO80 sites was dependent on 
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EZH2. Knockdown of EZH2 mRNA and protein levels with shRNA increased gene 
expression at NC-INO80 targets in HepG2 cells. Treatment of HepG2 cells with different 
EZH2 methyltransferase inhibitors decreased global levels of H3K27me3, led to 
increased levels of H3K27ac, and increased gene expression. Additionally, when 
H3K27me3 levels were following EZH2 inhibition, H3K27ac levels were increased at 
NC-INO80 targets, as well as other sites across the genome. These data indicated that 
EZH2 opposes gene activation and H3K27ac at these sites. Given that P300 is an 
H3K27 acetyltransferase that antagonizes H3K27me3, and that P300 interacts with 
INO80-C, we hypothesized that P300 and INO80-C may be jointly facilitate gene 
expression when H3K27me3 at NC-INO80 targets is reduced.  
 
Steps Toward Understanding EZH2-dependent Activation of NC-INO80 Targets 
To determine if INO80-C plays a role in activating NC-INO80 sites following 
perturbation of EZH2 methylation activity, we performed western blots for H3K27ac in 
the context of EZH2 inhibition and siRNA knockdown of INO80-C components. 
Strikingly, loss of the INO80 ATPase reduced levels of H3K27ac dramatically in EPZ-
6438 treated cells. Loss of MCRS1 had a similar effect in the same context. These data 
indicated that high levels of H3K27ac following EPZ-6438 treatment, and likely GSK126 
as well, in HepG2 cells depends on INO80-C. Additionally, these data indicate a critical 
role for INO80-C in facilitating the transition from inactive to active chromatin states in 
HepG2 cells that may be important in different biological contexts.  
We performed RNA-seq in HepG2 cells treated with EPZ-6438 to determine if 
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gene expression levels were similarly dependent on INO80-C. These data indicated the 
requirement of MCRS1 for activation of gene expression at NC-INO80 sites following 
knockdown of H3K27me3 with EPZ-6438. Because MCRS1 is a subunit of INO80-C 
that did not exhibit ChIP-seq signal at NC-INO80 sites in prior experiments, these data 
suggested that NC-INO80 targets were converted to Canonical INO80 targets following 
EZH2 inhibition, using MCRS1 as a surrogate for INO80-C in these studies. Additional 
evidence demonstrated that the INO80 ATPase is required for some, but not all, of the 
same effects. Indeed, there was an INO80-independent activation of NC-INO80 targets 
that depended on MCRS1 but not the INO80 ATPase. These data correlate with both 
INO80-dependent MCRS1 and INO80-independent MCRS1 functions, consistent with 
MCRS1 participating in separate biochemical complexes known to facilitate chromatin 
accessibility independently (Cai et al. 2010; Chelmicki et al. 2014).  
 We also performed ChIP-seq experiments using MCRS1 and YY1 as surrogates 
for the INO80-C to determine if NC-INO80 sites convert to Canonical INO80 
classifications following treatment with EPZ-6438. Interestingly, we did not observe 
changes in localization that correlated with the MCRS1-dependent gene expression 
changes at NC-INO80 or Canonical INO80 targets. Additionally, sites that had been 
previously classified as NC-INO80 in HepG2 cells exhibited higher signal for MCRS1 
and YY1 in this separate experiment than our previous studies had shown. There are 
several plausible explanations for this observation.  
For one, the overall signal for MCRS1 and YY1 are higher in this experiment than 
our previous experiments. Therefore sites that had previously escaped our 
categorization as NC-INO80 due to low signal for MCRS1 and YY1, may have displayed 
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higher signal in the second batch of experiments thus misconstruing our previous 
classifications based on INO80 ChIP-seq in untreated HepG2 cells. Nonetheless, the 
different levels of ChIP-seq signal for MCRS1 and YY1 in the chemical treatments 
indicates that our classifications of NC-INO80 and Canonical INO80 sites captured sites 
that were differentially targeted by these subunits, whereas INO80 signal was 
comparable at both classes in untreated HepG2 cells. Likewise, our extensive approach 
to corroborate INO80-C heterogeneity in additional ChIP-seq experiments in untreated 
Huh7 and using publicly available datasets in A549 strongly suggest our classifications 
are valid. To test our classifications in DMSO and EPZ-6438 treated HepG2 cells more 
appropriately, we should have included a control for INO80 ChIP-seq in our data 
following these treatments.  
Likewise, it is likely that PRC2 and H3K27me3 represent just one of several 
barriers to INO80-C targeting. Perhaps removing the catalytic activity of EZH2 is not 
sufficient to yield a local environment compatible for INO80-C retargeting on the level 
necessary to be detected by ChIP-seq. Removing EZH2 protein levels would test this 
hypothesis, which we attempted. However, we never achieved stable knockdown of 
EZH2 levels using shRNA or CRISPR gRNAs in HepG2 cells (data not shown), perhaps 
because EZH2 protein levels are required for the viability of HepG2 cells. Additionally, 
perhaps using multiple inhibitors to separate repressive chromatin regulators would 
sufficiently reset the chromatin state for INO80-C targeting to NC-INO80 sites. More 
likely, the appropriate co-activators to target these sites, such as developmentally 
regulated transcription factors that are repressed at NC-INO80 targets, are not 
expressed. Therefore, perhaps prolonged treatment with chemical or genetic tools to 
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activate these elements, or introducing the factors exogenously, would provide a more 
robust cellular response.  
Additionally, it is likely necessary to evaluate INO80-C heterogeneity and its 
contribution to chromatin accessibility and gene expression at NC-INO80 sites in a more 
dynamic cellular model than HepG2 cells. Given the association of NC-INO80 sites with 
developmental signaling pathways, it is possible that HepG2 cells are unable to fully 
activate these repressed targets because their biological networks are relatively 
inflexible. In contrast, embryonic stem cells (ES) may be a promising option to explore 
INO80-C heterogeneity further given the inherent plasticity of ES cell chromatin states 
(Mattout and Meshorer 2010; Guenther et al. 2010). The plastic state of the ES cell 
chromatin landscape potentiates the large-scale chromatin dynamics that facilitate 
changes in cell identity throughout differentiation. Mapping the localization of INO80-C 
as ES cells differentiate from a common progenitor (undifferentiated mouse ES) may 
provide a more robust model to derive the biological implications and mechanistic 
details of INO80-C heterogeneity. Finally, as technological advancements are made in 
the coming years we may be able to conduct more robust quantitative comparisons by 
ChIP-seq than current approaches provide. The multitude of possibilities reveal the 
limitations of using HepG2 cells to test the hypothesis that NC-INO80 sites are able to 
be converted to Canonical INO80 sites using ChIP-seq.  
Despite these limitations, we have provided a rigorous approach to INO80-C 
targeting that has not been conducted previously. Our investigations revealed that 
INO80-C is compositionally heterogeneous at its targets and that INO80-C is physically 
linked to the chromatin activator P300. Additionally, our comparisons of INO80-C 
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localization across cell-types revealed that correlations between INO80-C targeting and 
features of local chromatin landscape are strong. We further identified that INO80-C is 
globally required for the transition from inactive to active chromatin states, including 
gene expression at a subset of sites. While we did not resolve the mechanism of 
INO80-C targeting and functional output, we provided key steps toward its elucidation 
including the identifications of technical limitations given current approaches. Additional 
work must be done to test the molecular mechanisms of INO80-C targeting 
heterogeneity in a more biologically sensitive model and perhaps, with more robust 
experimental approaches.  
We propose that INO80-C and P300 jointly facilitate chromatin accessibility at 
loci required for active transcription, including promoters and enhancers. Our data 
suggest that the INO80 ATPase is a largely indiscriminate chromatin binding protein. 
Perhaps the INO80 ATPase binds widely to sample the epigenomic landscape at loci to 
determine if INO80-C assembly and co-recruitment with other activators is appropriate. 
This hypothesis is consistent with its known role as a biochemical scaffold (Chen et al. 
2011, 2013) and with biochemical data that suggest the INO80 ATPase awaits local 
signals and ATP levels before RUVBL1 and RUVBL2 facilite INO80-C assembly (Zhou 
et al. 2017). At repressed sites, PRC2, H3K27me3, and other heterochromatin signals 
may prevent assembly of INO80-C. In a subset of cells within a population, perhaps 
some of these sites are able to initiate partial or complete assembly of INO80-C. 
Collectively, our suggest that NC-INO80 and Canonical INO80 targets may exist on a 
spectrum of occupancy. To represent the data most accurately, we have designed a 
model that captures the heterogeneity in INO80-C binding that we observe across our 
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experiments (Fig. 5.1).  
 
 
Figure 5.1. Spectrum of INO80-C Assembly Genome-wide Based on Local 
Chromatin Features. We propose that INO80-C assembly is dependent, at least in 
part, on local chromatin features. PRC2 and other heterochromatin likely oppose 
assembly of INO80-C, whereas H3K27ac and P300 may promote assembly and 
remodeling activity by INO80-C.  
 
Future Directions 
One strength of our work is the characterization of INO80-C binding targets using 
its established protein subunits as representatives for identifying its targets. Using 
multiple protein subunits, from each known INO80-C module, across three cell lines we 
improved the field’s understanding of INO80-C targeting in contrast to prior work that 
often relies on a single subunit when defining INO80-C genomic activity. Additionally, 
our approach identified a subset of INO80-C targets in each cell line we tested that 
lacked signal for hallmark INO80-C subunits and harbored repressive chromatin and 
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gene regulatory signatures. Additionally, our findings are similar but likely distinct to a 
non-canonical version of INO80-C, named MINC, recently reported to suppress 
pervasive transcription in yeast and mouse ES cells (Xue et al. 2017). Two interrelated 
questions are raised based on our findings. 1) Are MINC and our classifications of 
INO80-C binding analogous? 2) What additional factors influence INO80-C targeting 
and function?  
To address the first question, it is worth revisiting biochemical evidence that the 
molecular assembly of INO80-C occurs in a stepwise fashion. Zhou et al. demonstrated 
that INO80-C subunits RUVBL1 and RUVBL2 function as INO80-C chaperones that 
guide assembly of the complex (Zhou et al. 2017). Additional evidence indicates 
subcomplexes of INO80-C exist in cells (Yao et al. 2015, 2016). In each case, INO80-C 
subcomplexes lack the ability to target and mobilize nucleosomes. Based on these data 
alone, it seems likely that incomplete subcomplexes of INO80-C form genome-wide that 
lack the ability to remodel chromatin. Moreover, the INO80 ATPase is known to be a 
scaffold for the rest of the complex in vitro (Chen et al. 2011, 2013). Therefore, one 
might hypothesize that the INO80 ATPase possesses the ability to exist in cells 
independently from INO80-C subunits in cells, awaiting appropriate signals to facilitate 
its molecular assembly.  
Indeed, we identified a subset of targets, named NC-INO80, that lack hallmark 
INO80-C subunits and occupy regions of repressive chromatin, suggesting INO80-C is 
unable to facilitate chromatin accessibility at these sites. These data support the 
hypothesis that INO80-C assembly occurs in a stepwise fashion and that if the INO80 
ATPase is the scaffold for INO80-C subunits, then perhaps incomplete INO80-C 
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subcomplexes exist in cells. In addition, we provided evidence that INO80-C functions 
as a facilitator or chromatin accessibility with the HAT P300. MINC, in contrast, targets 
similar chromatin features as both Canonical INO80 and NC-INO80, but has been 
proven to suppress transcription (Xue et al. 2017). We did not find evidence that NC-
INO80 targets uniformly de-repressed following knockdown of INO80-C, as a MINC-
related function would have predicted. It would be interesting to map MINC members 
MOT1 and NC2 in HepG2, Huh7, and A549 cells to determine if the proteins associate 
with INO80-C targets we defined. Without that evidence, we propose that MINC is a 
specialized version of INO80-C that functions to suppress transcription and maintain 
genomic integrity, whereas Canonical INO80 and NC-INO80 classes are related to 
INO80-C assembly. Distinguishing these categories in future work will be important for 
INO80-C biology.  
Based on evidence for heterogeneity in INO80-C, it will be beneficial to apply 
proteomic approaches to determine if different cell types harbor different subunit 
compositions of INO80-C or possess novel INO80-C interacting partners. MINC showed 
that INO80-C physically interacts with novel partners to perform distinct a suppressive 
function. Our work suggested that established INO80-C subunits mediate chromatin 
accessibility with P300. Examining the extent of INO80-C co-regulatory partners 
presents an exciting avenue for future research. Additionally, whether INO80-C exists in 
additional, lineage or cell type restricted formations will be of critical interest to the 
chromatin field. The SWI/SNF remodeler for example, exhibits plasticity in its 
composition in developmental and disease contexts, perhaps even in the same cell type 
(Hodges et al. 2016). Unbiased proteomic approaches will clarify the abundance of 
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MINC as a distinct complex and P300 as an co-factor with INO80-C across cell types, 
and contribute additional layers to the understanding of INO80-C compositional 
multiplicity.  
Likewise, evidence suggests that chromatin regulators can be modified by post-
translational means (Morrison et al. 2007; Ferreira et al. 2007; Wang et al. 2014b; Lee 
et al. 2014a). The complete array of biological settings for these modifications are 
unknown. For INO80-C, the complex is known to be phosphorylated for its role in DNA 
Damage Response (Morrison et al. 2007) and ubiquitinated at replication forks (Lee et 
al. 2014a). It will be important to investigate the array of post-translational modifications 
by which the complex may be modified. Based on our evidence, it is possible that 
INO80 ATPase is modified by P300, which is known to acetylate its interacting partners, 
differentially modifies INO80-C at sets of loci such as MINC, NC-INO80, and Canonical 
INO80 targets. Perhaps INO80-C is subject to PTMs that signal its molecular assembly 
in cells.  
Alternatively, modifications to histones may be one mechanism that directs 
INO80-C assembly at specific targets. We provide evidence that H3K27 modifications 
correlate with the ability of INO80-C target and assemble. Additional evidence supports 
a model that chromatin landscape guides INO80-C function. For example, the E3 
ubiquitin ligases RNF20/RNF40 have been shown to antagonize INO80-C binding and 
H2AZ exchange (Segala et al. 2016). Segala et al. demonstrated that the INO80 
ATPase interacts with RNF40, which deposits ubiquitin onto H2B, restraining H2AZ in 
target nucleosomes by preventing INO80-C-mediated H2AZ eviction. When H2B is 
unmodified by RNF40, INO80-C is able to remove H2AZ. Interestingly, our data 
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indicates that H2AZ is enriched at Canonical INO80 but not NC-INO80 targets in HepG2 
cells (Fig. 5.2). Therefore it is unlikely that NC-INO80 targets represent H2B 
monoubiquitinated histones, which lack INO80 ATPase targeting and are enriched for 
H2AZ (Segala et al. 2016). In turn, H2AZ and H2B-ub levels may guide targeting by 
Canonical INO80 to additional subsets of genomic sites, distinct from NC-INO80 
targets. Are additional histones modifications like H2B monoubiquitination involved in 
INO80-C targeting and assembly? Exploring this hypothesis will offer exciting insight 
into multivalent chromatin regulation. Perhaps there exists multivalent coordinated 
machinery by which INO80-C targeting and assembly depends.  
 
Figure 5.2. Variant Histone H2AZ is Enriched at Canonical INO80 but NC-
INO80 Targets. A. Metaplot centered on Canonical INO80 and NC-INO80 sites for 




Examining crosstalk between INO80-C, PRC2, and P300 will likely be important 
in developmental contexts, where the INO80 ATPase has been shown to be important 
for various developmental programs (Min et al. 2013; Wang et al. 2014a; Serber et al. 
2016; Qiu et al. 2016). Investigative developmental studies involving changes in cell 
identity that lead to redistribution of chromatin programs will be an important extension 
of the work completed in this thesis. For example, measuring levels of INO80-C 
subunits, PRC2, and P300 in undifferentiated mouse ES cells into endoderm, 
mesoderm, ectoderm lineages will allow for the characterization of INO80-C targets 
across biologically-relevant developmental timepoints. An additional question regarding 
Canonical INO80 and NC-INO80 targets is how they are distributed in mouse ES cells 
in the context of bivalent chromatin, where active and repressive features are both 
enriched in order to prime cells for lineage commitment (Bernstein et al. 2006; Voigt et 
al. 2013). These data would enable a global survey of INO80-C relationships as they 
pertain to chromatin features, dynamic epigenomic changes, and cell identity.   
 
Translational Implications 
 Given the broad role for INO80-C in mediating transcriptional programs through 
epigenomic regulation, the implications for INO80-C compositional heterogeneity in 
pathogenic contexts are broad. In the scenarios described below, we propose that 
perturbations to the chromatin landscape may initiate global transformations in 
chromatin signaling pathways, including INO80-C localization and remodeling function. 
In some cases, INO80-C itself is perturbed, indicating the need to clarify changes to 
regulatory programs that may be INO80-C dependent. Alternatively, INO80-C may be 
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involved in facilitating pathogenic programs indirectly when the function of other 
chromatin regulators are perturbed, leading to misregulation of INO80-C targeting and 
remodeling activity genome-wide. Investigating the function of INO80-C in all these 
contexts will be critical to evaluating the output of INO80-C in cell biology.  
 
Perturbation of INO80 in Lymphomas Subtypes  
 A series of discoveries pointed toward a relationship between loss or mutation of 
the INO80 ATPase in lymphomas. These reports are observational in nature, indicating 
experimental work should be conducted to clarify the function of INO80 in the 
physiologic development and biological function of cells that give rise to these types of 
cancer, in instances where the cell-type of origin is known. Likewise, investigation into 
the potential pathogenic roles of INO80-loss in these tumors should be explored. In this 
section, the existing knowledge on INO80 perturbation in lymphomas will be described. 
 The first report of INO80 perturbation in a lymphoma described an atypical 
clinical case of B cell derived neoplasm. The patient was described as a white 9 year 
old male that presented with circulating cells that morphologically and immunologically 
resembled Burkitt lymphoma (Smith et al. 2015). However, Burkitt’s lymphoma is 
characterized by translocations on chromosome 8 that activate the oncogene MYC 
(Erikson et al. 1983; Boxer and Dang 2001; Schmitz et al. 2014). The unique case 
reported by Smith et al. harbored a translocation t(11;15) (q23;q15) that leads to loss of 
INO80. The authors reported the absence of MYC activation, inconsistent with Burkitt’s 
lymphoma and a mixed mature-immature cell phenotype, consistent with B 
 136 
lymphoblastic leukemia. In addition, B lymphoblastic leukemia exhibits a range 
chromosomal rearrangements and karyotypic abnormalities (Mullighan 2012; Zhang et 
al. 2017a). Therefore the authors describe the clinical case as a patient presenting with 
a unique translocation in B lymphoblastic leukemia. A causative role for INO80 loss in 
the pathogenesis of this patient’s disease has not been determined. Likewise, any 
known function for INO80-C in lymphoid cells is currently unexplored. 
 Interestingly, whole-exome sequencing studies yielded additional reports of 
aberrations to INO80 in lymphoma subtypes. INO80 was among the most commonly 
mutated proteins in Diffuse Large B Cell Lymphoma (DLBCL) and Hepatosplenic T-cell 
Lymphoma in work conducted by The Cancer Genome Atlas and others (McKinney et 
al. 2017; Reddy et al. 2017). Loss of INO80 was reported to occur in approximately 10% 
of DLBCL (Reddy et al. 2017). INO80 was mutated in 21% of Hepatosplenic T-cell 
Lymphoma (McKinney et al. 2017). In the former, INO80 also exhibited a co-occurrent 
relationship with CD79B, which is associated with immune-privileged DLBCL sites 
(Kraan et al. 2013) and has been shown to confer resistance acquire to a common 
lymphoma treatment that blocks B cell receptor signaling (Kim et al. 2016). INO80 
exhibited a mutually exclusive mutation relationship in DLBCL with IRF8, a myeloid-
specific transcription factor that is required for development of germinal centers from 
which most DLBCLs are derived (Reddy et al. 2017). Additionally, in DLBCL IRF8 is 
regulated by enhancers sensitive to the BRD4-inhibitor JQ1, which reduces DLBCL 
proliferation (Chapuy et al. 2013). The high rate of INO80 mutation and loss in 
lymphoid-derived tumors, as well as its relationship to well-studied factors that promote 
lymphoma, suggest INO80 may play an important role in normal lymphoid development 
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and when perturbed, may potentiate lymphomagenesis. 
 Despite the accumulating evidence for INO80 aberrations in lymphoma, no 
studies have investigated the mechanistic contributions of INO80 in lymphoid 
development or tumors derived from lymphoid lineages. As a result, determining a direct 
role for INO80 in these contexts is years away. Nonetheless, the function of INO80-C in 
these contexts ought to be explored in earnest given the high rate of perturbation of the 
INO80 ATPase in studies investigating the mutational spectrum of these tumors. 
 
Mutations to Enzymes that Modify Chromatin in B Cell Lymphomas 
 In contrast to loss or mutation of INO80 which may directly contribute to 
lymphomagenesis in ways that have not yet been determined, mutations to the histone 
modifying enzymes that govern the function of INO80-C may be fruitful for investigating 
indirect contributions of INO80-C function in pathology. B cell lymphomas are 
particularly susceptible to mutations in histone modifiers including EZH2 and CBP, and 
to a lesser extent P300 (Pasqualucci et al. 2011; Shaknovich and Melnick 2011; Morin 
et al. 2011). In this section, the influence that these mutations may have on INO80-C 
function will be briefly explored.  
 Mutations to EZH2 in lymphomas were discovered in targeted sequencing efforts 
(Morin et al. 2010) and whole-exome sequencing (Morin et al. 2011; Lohr et al. 2012). 
Early in vitro data suggested that the predominant mutation to EZH2 in B cell 
lymphomas, Y641F, reduced EZH2 enzymatic activity (Morin et al. 2010). However, 
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subsequent evidence indicated that EZH2 mutations yield increased H3K27me3 in 
lymphomas (Sneeringer et al. 2010; Yap et al. 2011). Subsequently, it was discovered 
that aberrant epigenomic silencing by EZH2 contributed to lymphomagenesis 
(Velichutina et al. 2010). A separate mutation to EZH2, A677G, also promotes elevated 
levels of H3K27me3 levels in B cell lymphomas (McCabe et al. 2012). Interestingly, 
Souroullas et al. confirmed that H3K27me3 levels globally increase in mice that bear 
homologous Y641 mutations, with additional data indicating H3K27me3 is also 
redistributed genome-wide leading to sets of sites in tumor cells that more H3K27me3 
(hypertrimethylated) or less H3K27me3 (hypotrimethylated) as a result (Souroullas et al. 
2016). In addition, the homologous Y641 mutations in mice induced bidirectional 
changes in gene expression, correlating with redistribution of H3K27me3-mediated 
repression across the genome (Souroullas et al. 2016). Sourollas et al. also 
demonstrated that genes nearby distal sites that lose H3K27me3 become activated. 
These genes contain regulatory elements that resemble enhancers that are silenced in 
normal B cells. Collectively, these data indicate that perturbation of EZH2 leads to 
epigenomic changes in chromatin signaling that facilitates tumorigenesis.   
 In relation to INO80-C, our evidence indicates that EZH2 and its parent complex 
PRC2 oppose the activating function, and perhaps the molecular assembly of INO80-C 
at a subset of its remodeling targets. Given our assessment that INO80-C is 
predominantly involved in chromatin accessibility that yields gene activation in multiple 
cell types, it is likely that INO80-C facilitates gene programs in tumorigenic contexts as 
well. If PRC2 or other Polycomb components oppose the formation of Canonical INO80-
C at repressed sites, then redistribution of EZH2 and H3K27me3 could consequently 
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drive INO80-C to new targets, including those involved in initiating, propagating, or 
maintaining cancer biology.  
 Notably, B cell lymphomas harboring mutations to EZH2 have been shown to be 
sensitive to inhibition of EZH2 methyltransferase activity (Knutson et al. 2014). Inhibition 
of EZH2 yields global reduction in H3K27me3 and a consequent increase in H3K27ac, 
(Tie et al. 2009; Knutson et al. 2014) (Fig. 4.10, 4.11) per antagonism between the two 
opposing histone modifications and their writer enzymes. If EZH2 inhibition changes the 
epigenome oppositely from its tumor-promoting state, and high levels of H3K27ac leads 
to gene activation dependent on chromatin programs mediated by INO80-C (Fig. 4.14, 
4.15), then INO80-C may likely be involved in re-instituting non-pathogenic epigenomic 
programs in EZH2-mutant tumor cells. Mechanistically, it may be worth exploring 
whether INO80-C localization changes in the context of wild-type versus mutant EZH2, 
and also in EZH2-inhibitor treated EZH2 mutant cells in order to test a model for 
heterogeneity in INO80-C localization and dynamics following clinically-relevant EZH2 
perturbations. Because signaling between enzymes that oppositely modify chromatin is 
involved in facilitating the changes to cell identity, then INO80-C may likely play an 
intermediary role. If so, then perturbation of INO80-C targeting or function may prove to 
be an indirect mechanism of reducing the tumorigenic effect of mutant EZH2 or 
enhancing the tumor-regressive effect of EZH2 inhibition.  
 Similarly to EZH2, the HATs CBP and P300 are subject to frequent mutation in B 
cell lymphomas (Morin et al. 2011). Mutations in HATs in DLBCL are definitively 
inactivating (Pasqualucci et al. 2011). They are also frequent. In fact, 39% of DLBCL 
harbor mutations that inactivate CBP or P300 (Pasqualucci et al. 2011). CBP has 
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subsequently been validated as a haploinsufficient tumor suppressor, cooperating with 
BCL2 overexpression to drive lymphogenesis in mice (Zhang et al. 2017b). In view of 
EZH2 mutations that increase H3K27me3 globally, loss-of-function HAT mutations that 
lead to reduced H3K27ac and increased H3K27me3 through diminished balance 
between H3K27ac and H3K27me3 antagonism, represent similar regulatory outcomes. 
Consistently, mutation to CBP and EZH2 are co-occurring events in DLBCL (Reddy et 
al. 2017). No relationship was determined between mutation to EZH2 and P300. 
However, there is evidence that CBP-deficient DLBCLs are addicted to P300 (Ogiwara 
et al. 2016). Recently, a P300 inhibitor have been developed (Lasko et al. 2017) that 
may be viable CBP-deficient tumors. Interestingly, haploinsufficient loss of CBP does 
not dramatically decrease the levels of H3K27ac, and H3K27ac and CBP are primarily 
co-localized at enhancer regions in wild-type B cells (Zhang et al. 2017b). These data 
suggest, as the authors conclude, that enhancer networks and subsets of sites with 
locally diminished or redistributed H3K27ac levels following loss of CBP drive gene 
expression changes that facilitate lymphomagenesis. These are the sites that may be 
particularly susceptible to P300 inhibition.    
 As with EZH2-mutant lymphomas, mutations to HATs in DLBCL present an 
opportunity to evaluate the role of INO80-C in a disease-specific context. INO80-C may 
play an indirect role in facilitating the chromatin and gene expression changes that drive 
lymphomagenesis. Additionally, if INO80-C localization varies in the context of EZH2 
mutation, or CBP or P300 loss, then there could be a meaningful role for INO80-C in 
activating chromatin targets and driving epigenomic programs in lymphoma.  
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Enhancer-Rewiring in B Cell Lymphomas 
Other mechanisms exist in B cell lymphomas that lead to activation of proto-
oncogenes at the transcriptional level. In numerous nonlymphoid cancers, chromosomal 
rearrangements potentiate the formation of chimeric proteins derived from fusion 
transcripts (Meyerson et al. 2010). Notably, there are numerous recurrent chromosomal 
rearrangements in B cell lymphomas (Küppers and Dalla-Favera 2001; Ryan et al. 
2015). In this section, the consequences that chromosomal rearrangements on gene 
expression will be briefly introduced and hypotheses for the role of INO80-C in this 
context will be drawn.  
B cell lymphoma rearrangements are thought to lead to aberrant activation of 
intact proto-oncogenes through either enhancer hijacking or enhancer amplification, 
which have been shown in nonlymphoid tissues to stimulate the activity of enhancers 
and increase mRNA transcripts of enhancer-targeted genes (Shi et al. 2013; Northcott 
et al. 2014). Genomics-based approaches have identified series of enhancer 
duplication, deletion, or amplification in B cell lymphomas, which lead to aberrant 
activation of B cell lymphoma oncogenes such as MYC and BCL6 (Ryan et al. 2015). 
Additionally, proteins from the NOTCH signaling pathway are subject to chromosomal 
rearrangements that inappropriately stimulate NOTCH-dependent enhancers, including 
MYC (Ryan et al. 2017). These events require P300 and the transcription factor 
MEF2B, both of which INO80-C has been linked to in work described in this dissertation 
(Fig. 3.5B-C, Fig. 4.9B, respectively). Whether INO80-C intersects with these re-wiring 
events in B cell lymphoma is unknown, but an exciting topic for investigation. Moreover, 
one interesting angle to approach the question would be to investigate whether 
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Canonical INO80 and NC-INO80 targets are redistributed to new targets in the context 
of these genome-wide scale chromatin rearrangements. Perhaps INO80-C is part of the 
machinery that activates the aberrant transcriptional programs that result.  
 For example, mice harboring concomitant EZH2 mutations and BCL-
overexpression lead to accelerated development of B cell lymphomas (Souroullas et al. 
2016). Ryan et al. demonstrated that EZH2 mutations frequently co-occur with BCL2 
activating rearrangements in B cell lymphomas (Ryan et al. 2011). It is likely that 
INO80-C plays at least a peripheral role in facilitating the chromatin changes and gene 
expression consequences.  
It is obvious that there is strong evidence for chromatin perturbations in B cell 
lymphoma. This makes studying B cell lymphoma an excellent model for exploring 
crosstalk between chromatin regulators. Additionally, given the dearth of information 
regarding INO80-C function in pathology and the high rate of mutation of INO80 in B cell 
lymphoma, there is an abundance of interesting mechanistic questions to be asked. 
Additionally, the association between INO80-C and histone modifying enzymes that are 
commonly mutated in lymphoma underscores the need to explore the consequences 
that mutation to histone modifying proteins has on the molecular assembly and function 
of INO80-C. Additionally, these topics offer the benefit of potential therapeutic insight for 




Other Perturbations to Chromatin Landscape 
 B cell lymphomas are not unique in their perturbations of endogenous 
mechanisms of epigenomic regulation. Many chromatin modifying proteins have been 
proven to drive various forms of cancer (Flavahan et al. 2017), developmental disorders 
(Butler et al. 2012), and neurological diseases (Maze et al. 2013), among forms of 
pathology. Interestingly, mutations to histone proteins have been discovered to be 
common in several rare forms of cancer. Notably, mutations to histone 3 in diffuse 
intrinsic pontine glioma (DIPG) have been shown to perturb PRC2 function. The 
mutations comprise mutations that convert lysine 27 of histone variant 3.3 to a 
methionine (H3K27M), rendering the target of EZH2 unable to be modified by the 
enzyme. This yields elevated levels of H3K27ac genome-wide (Lewis et al. 2013; Piunti 
et al. 2017; Mohammad et al. 2017). Additionally BET inhibitors show promise in the 
context of H3K27M mutations (Piunti et al. 2017), indicating the interplay between 
various chromatin regulators contribute to DIPG pathogenesis. Whether INO80-C 
contributes to these and other disease mechanisms remains an open question.  
  
Final Remarks 
One of the major topics in biomedical investigation over the several decades will 
be to elucidate the details of how chromatin modifying enzymes contribute to cellular 
programs. Abundant evidence indicates that an array of homeostatic and pathologic 
programs require the coordinated activities of chromatin modifying enzymes. However, 
a only a fraction of activities and biological contexts have been investigated in depth. 
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Advancements in chromatin biology have provided new insights into animal 
development, disease mechanisms, and therapeutic avenues. Nonetheless, new 
questions have emerged that demand rigorous investigation. Among the most pressing, 
is how do the proteins and enzymes that regulate biological programs function jointly or 
oppositely? This question formed the crux of this dissertation.  
  Decades of work has revealed the complicated networks in which chromatin 
modifying enzymes operate. Interestingly, antagonism between active and inactive 
chromatin states remains a topic of debate and fascination. Two histone PTMs, in 
particular, fuel many questions in chromatin biology.  
The activating H3K27ac and inactivating H3K27me3 represent discrete classes 
of chromatin accessibility and regulatory activity. Inappropriate regulation of the 
machinery that controls whether a site accumulates H3K27ac or H3K27me3 is sufficient 
to drive pathology. In general, we understand the principles of how these modifications 
are deposited, read, and removed by cells (Chapter 1). However, the steps that lead to 
these processes as well as the consequences of perturbing these steps, remain largely 
unclear.  
The work in this dissertation was derived from the concept that the protein 
complexes that regulate chromatin accessibility are dependent on local chromatin 
architecture to function. Movers, in particular, had not been thoroughly investigated for 
their contribution to or dependency on local chromatin state and histone PTMs. One 
hypothesis was that the proteins that comprise of movers facilitate their function at their 
genomic targets (Chapter 2). If true, perhaps variable mover composition indicates that 
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movers possess numerous functions that are determined by unique composition 
throughout the genome. Subsets of mover targets may possess differing chromatin 
state or gene expression outputs based on the components of a mover that bind those 
sites.  
INO80-C was chosen as a candidate to explore the relationship between movers 
and histone PTMs given the lack of data on the complex and its presumably 
homogeneous composition in cells. Unexpectedly, work in this thesis contributed to a 
growing body of evidence that INO80-C is far more heterogeneous than anticipated. 
Our work demonstrated that two classes of INO80-C targeting exist in human cells. One 
class contains the established components of INO80-C and associates with active 
chromatin states and high levels of gene expression of nearby genes. A second class 
contains an incomplete or non-canonical INO80-C that correlates with inactive 
chromatin states and low levels of gene expression. These data indicated that 
composition of INO80-C is either dependent on local chromatin architecture or vice 
versa (Chapter 3). 
We investigated the mechanisms underlying the heterogeneity (Chapter 4). We 
tested whether there was an antagonistic relationship between INO80-C and PRC2 at 
NC-INO80 targets. These results provided compelling insight into how PRC2 and 
INO80-C combinatorially regulate their chromatin co-localized targets. We 
demonstrated that INO80-C is involved in facilitating the transition from inactive to active 
chromatin. Likewise, INO80-C appeared to jointly regulate chromatin accessibility with 
P300, suggesting a link between H3K27 regulation and opposition to H3K27me3. These 
results provided important insight into INO80-C function, P300-mediated chromatin 
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accessibility, and PRC2-mediated chromatin inaccessibility.  
 Numerous exciting avenues for future research emerged from this thesis. It will 
be exciting to determine the multifaceted aspects that direct INO80-C to its targets, 
modulate its local assembly, and control its function in chromatin regulation (Chapter 5). 
There may be implications for INO80-C and its relationship with other chromatin 
modifying enzymes such as P300 and EZH2 in facilitating chromatin architecture in 
pathology. Investigative efforts into the contribution of INO80-C in the context of 
diseases such as B cell lymphoma are likely to be high yield for understanding 
pathogenic mechanisms, dependencies, and sensitivities to therapeutic intervention.  
 The past five years have led to a surge in information relating to the 
combinatorial regulation of chromatin by enzymes that modify chromatin accessibility 
and gene expression. Decoding the vast array of information embedded in chromatin 
architecture will enable future scientists to understand new principles of physiology and 
pathophysiology that emerge over time. Thanks to diverse and exciting discoveries in 
chromatin biology over the past several years, investigating the networks of chromatin-
based signaling will be a prominent field for years to come.
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